

**Wednesday, 08. June 2022***Opening Plenary*

18:25 - 19:55

R1

**Opening Plenary****Welcome Address**

18:25 - 18:25

*Moderator:* Isabelle Fajac, FR**Welcome Address**

18:25 - 18:25

*Moderator:* Harm Tiddens, NL**Motion is the only permanent condition that exists, it dictates everything**

18:25 - 18:25

*Moderator:* Harm Tiddens, NL**Presentation of the ECFS Award**

18:25 - 18:25

**ECFS Award Lecture**

18:25 - 18:25

*Speaker:* Kris De Boeck, BE**Presentation of the Gerd Döring Award**

18:25 - 18:25

**The impact of European patient organisations**

18:25 - 18:25

*Speaker:* Jacqueliën Noordhoek, NL**Presentation of the CFE Advocacy Award**

18:25 - 18:25

*ECFS Tomorrow Lounge Session*

20:00 - 21:30

**Welcome Reception**

**Thursday, 09. June 2022***Symposium*

08:30 - 10:00

R1

**S01 - Symposium 1 - CF Research in the roaring twenties***Chair:* Damian G Downey, GB*Chair:* Kors Van der Ent, NL**Sense or nonsense of theratyping**

08:30 - 08:52

*Speaker:* Margarida Amaral, PT**Repair versus modulation: what's best?**

08:52 - 09:14

*Speaker:* George Retsch-Bogart, US**Decentralisation of clinical care and randomised clinical trials**

09:14 - 09:36

*Speaker:* Nicholas Simmonds, GB**Novel imaging end-points in clinical trials**

09:36 - 10:00

*Speaker:* Pierluigi Ciet, NL*Symposium*

08:30 - 10:00

R2

**S02 - Symposium 2 - New antimicrobial therapy****At the end of the session, the participant will be able to:**

- Synthetize knowledge on antibiotic combination therapies in the management of people with CF
- Formulate a clear opinion on the value of hyperbaric oxygen therapy
- Appraise the place of inhaled amikacin in the CF therapeutic arsenal
- Understand the contribution of whole genome sequencing in predicting phenotypic *P. aeruginosa* resistance

*Chair:* Aurélie Crabbé, BE*Chair:* Geneviève Héry Arnaud, FR**How and when can the use of combination therapy be relevant?**

08:30 - 08:52

*Speaker:* Oana Ciofu, DK**Hyperbaric oxygen therapy for the treatment of pulmonary infections in cystic fibrosis**

08:52 - 09:14

*Speaker:* Mette Kolpen, DK**Amikacin liposome inhalation suspension in cystic fibrosis**

09:14 - 09:36

*Speaker:* Jakko van Ingen, NL**Inferring antimicrobial resistance of *P. aeruginosa* from whole genome sequencing**

09:36 - 10:00

*Speaker:* Helle Krogh Johansen, DK

## Symposium

08:30 - 10:00

R3

**S03 - Symposium 3 - Clinical Responses to CFTR modulator therapy from cell to patient****At the end of the session, the participant will be able to:**

- Describe what represents an effective CFTR modulator medication from a basic science perspective
- Summarize what response to CFTR modulator therapy clinicians believe to be significant
- Relate objective clinical trial endpoints to symptom and patient related outcomes
- Predict what future care for people with CF who respond to CFTR modulators may look like

Chair: Clémence Martin, FR

Chair: Daniel Peckham, GB

**What is a positive response to CFTR modulator therapy - a scientist's perspective** 08:30 - 08:52

Speaker: Jeffrey Beekman, NL

**What is a positive response to CFTR modulator therapy - a clinician's perspective** 08:52 - 09:14

Speaker: Barry Plant, IE

**What is a positive response to CFTR modulator therapy - a patient's perspective** 09:14 - 09:36

Speaker: Audrey Chansard, FR

**Projections for future care for people who respond to CFTR modulator therapy** 09:36 - 10:00

Speaker: Jane Davies, GB

## Symposium

08:30 - 10:00

R4

**S04 - Symposium 4 - Out in the wilderness: Transplantation and the co-ordination of care****At the end of the session, the participant will be able to**

- understand the importance of discussing "the elephant in the room" when raising the topic of transplantation with patients. Learning how to discuss the hope of transplantation alongside the real possibility that dying (before; during or after transplantation) is also a reality.
- review best practice - what can we learn from different practices across Europe?
- discuss the importance of ensuring that patients are appropriately reviewed post-transplant and there is someone co-ordinating care between post-transplant physicians and the CF Team.
- Discuss how to deal with anxiety and depression, common issues after transplant

Chair: Dorien Holtslag, NL

Chair: Tina D'Hondt, BE

**Overview of long-term transplant care in Europe** 08:30 - 08:52

Speaker: Espérie Burnet, FR

**Preparing your patient for life and death - striking the balance between hope and defeat** 08:52 - 09:14

Speaker: Sarah-Jane Mead-Regan, GB

**Sharing the follow-up - best supportive care** 09:14 - 09:36

Speaker: Thomas Kurowski, CH

**Hoping; coping; feeling. Living life after transplant** 09:36 - 10:00

Speaker: Trudy Havermans, BE

## Symposium

08:30 - 10:00

R5

**S05 - Symposium 5 - A whole new world - Physiotherapy management in good responders to modulator therapy: ideas please!****At the end of the session, the participant will be able to:**

- Adapt to physiotherapy management and their consequences in treating patients who are good responders to modulator therapy.
- Increase knowledge in mucoactive agents use in good responders to modulator therapy.
- Identify what are the changes in physiotherapy management during pregnancy in the good responders to modulator therapy. Continue or stop modulator therapy? What are the physiotherapeutic consequences in the different situations?
- Discuss the barriers to physiotherapy treatment in the era of CFTR modulators and formulate goals.

Chair: Marlies Wagner, AT

Chair: Jana Plešková, CZ

**CF Physiotherapy Management: A time for change?** 08:30 - 08:52

Speaker: Wytze Doeleman, NL

**Mucoactive agents: to take or not to take, that is the question.** 08:52 - 09:14

Speaker: Pamela McCormack, GB

**Pregnancy - what are the ch-ch-ch-changes (chances, choices, challenges)** 09:14 - 09:36

Speaker: Mathilde Legueult, FR

**Adherence; the eternal battle** 09:36 - 10:00

Speaker: Klára Benešová, CZ

## Symposium

08:30 - 10:00

R6

**S06 - Symposium 6 - Understanding the mechanisms of CFTR modulation****At the end of the session, the participant will be able to:**

- Assess progress towards developing small molecule therapies for premature termination codon variants in CFTR
- Discuss the molecular mechanisms of action of CFTR-targeted therapies
- Compare and contrast the efficacy of CFTR rescue using CFTR-targeted therapies and proteostasis modulators, which target CFTR-interacting proteins

Chair: Miquéias Lopes Pacheco, PT

Chair: Ineke Braakman, NL

**eRF1 as a target for readthrough of CFTR nonsense mutation** 08:30 - 08:52

Speaker: Steven M. Rowe, US

**Mechanism-based corrector combinations to rescue CFTR misfolding** 08:52 - 09:14

Speaker: Ineke Braakman, NL

**Novel targets to rescue the plasma membrane trafficking and stability of CFTR mutants** 09:14 - 09:36

Speaker: Carlos M Farinha, PT

**Co-potential to maximize the rescue of CFTR gating mutants** 09:36 - 10:00

Speaker: Guido Veit, CA

*ECFS Tomorrow Lounge Session*

10:00 - 10:30

**ECFS Clinical Trials Network Roundup: Now and Ahead***Chair:* Damian G Downey, GB*Symposium*

10:30 - 12:00

R1

**S07 - Symposium 7 - Infection beyond CFTR modulators****At the end of the session, the participant will be able to:**

- Synthesise knowledge on the effect of CFTR modulators on both classical CF pathogens and other members of the CF microbiome
- Understand how pathogens such as *P. aeruginosa* can have an impact on the effect of CFTR modulators
- Understand the changes caused by the effects of CFTR modulators in the clinical management of infection
- Discuss about potential strategy to combine CFTR modulators and antibiotic therapy to better manage chronic infection in CF.

*Chair:* Tom Coenye, BE*Chair:* Tavs Qvist, DK**Microbial epidemiology of cystic fibrosis in the CFTR modulator era: what has changed?**

10:30 - 10:52

*Speaker:* Geneviève Héry Arnaud, FR**Does CFTR correction influence the microbiome of the gut and lung in CF patients**

10:52 - 11:14

*Speaker:* Simon Y. Graeber, DE**Impact of *Pseudomonas aeruginosa* infection on CFTR function and correction**

11:14 - 11:36

*Speaker:* Emmanuelle Brochiero, CA**Do CFTR modulators change treatment of infection and clinical outcomes?**

11:36 - 12:00

*Speaker:* Edith Zemanick, US*Symposium*

10:30 - 12:00

R2

**S08 - Symposium 8 - Monitoring cystic fibrosis in 2022 - Research tools or ready for clinic?****At the end of the session, the participant will be able to:**

- Evaluate the utility of CT imaging in routine cystic fibrosis care
- Appraise the arguments for and against the use of routine CT imaging in cystic fibrosis care
- Appraise the arguments for and against the routine use of multiple breath washout technologies in cystic fibrosis care
- Question the use of current routine monitoring strategies in cystic fibrosis care

*Chair:* Michael Fayon, FR*Chair:* Anna Shawcross, GB**CT is ready for routine clinical practice - PRO**

10:30 - 10:48

*Speaker:* Harm Tiddens, NL**CT is not ready for routine clinical practice - CON**

10:48 - 11:06

*Speaker:* Patrick Flume, US**Discussion**

11:06 - 11:15

**Multiple Breath Washout is ready for routine clinical practice across the age groups - PRO**

11:15 - 11:33

*Speaker:* Alexander Horsley, GB

**Multiple Breath Washout is not ready for routine clinical practice across the age groups - CON** 11:33 - 11:51

*Speaker:* Sanja Stanojevic, CA

**Discussion** 11:51 - 12:00

#### Symposium

10:30 - 12:00

R3

#### **S09 - Symposium 9 - Inflammation in early CF lung disease**

**At the end of the session, the participant will be able to:**

- Describe the potential cause of early cystic fibrosis lung disease
- Recognize the role of oxidative stress in early CF pathogenesis
- Examine the role of inflammatory cells in early CF lung disease
- Summarize techniques to monitor inflammation in clinical and research environments

*Chair:* Olaf Eickmeier, DE

*Chair:* Robert Gray, GB

**What starts CF airway disease? Inciting events, progression and potential reversibility** 10:30 - 10:52

*Speaker:* Rabin Tirouvanziam, US

**Measurement of oxidative stress in early CF** 10:52 - 11:14

*Speaker:* Malcolm Brodlie, GB

**Role of neutrophils and macrophages in early CF** 11:14 - 11:36

*Speaker:* Luke Garratt, AU

**Monitoring inflammation in early CF** 11:36 - 12:00

*Speaker:* Hettie Janssens, NL

#### Symposium

10:30 - 12:00

R4

#### **S10 - Symposium 10 - Ethics in genetics**

**At the end of the session, the participant will be able to:**

- Discuss current ethical issues in relation to genetics and CF newborn screening
- Be aware of the challenges of identifying new, rare, equivocal and single CFTR genetic variants
- Understand how CFTR modulators are impacting CFTR screening practices

*Chair:* Suzanne van de Vathorst, NL

*Chair:* Domenico Coviello, IT

**The history and future in ethics of genetic screening (including how to manage incidental findings in general)** 10:30 - 10:52

*Speaker:* Eline Bunnik, NL

**What to do with CFTR variants as incidental findings?** 10:52 - 11:14

*Speaker:* Giuseppe Castaldo, IT

**Genetic counseling in the era of CFTR modulators: towards harmonization?** 11:14 - 11:36

*Speaker:* Danieli Salinas, US

**Newborn screening for disease panels: what's next (future of NBS: simultaneous testing of numerous diseases using genetic analysis either as a 2nd tier step after biochemical tests or as a 1st tier step)** 11:36 - 12:00

*Speaker:* Naama Orenstein, IL

*Symposium*

10:30 - 12:00

R5

**S11 - Symposium 11 - Individual cell cultures as biomarkers of CFTR function****At the end of the session, the participant will be able to:**

- Understand methods for CFTR function measurement in patient-derived intestinal organoids
- Understand methods for CFTR function measurement in patient-derived airway cells
- Explain overlap and differences between intestinal and airway culture models
- Express complementary value of in vitro and in vivo biomarkers of CFTR function

*Chair:* Jeffrey Beekman, NL*Chair:* Anabela Santo Ramalho, BE**Defining diagnostic criteria for cystic fibrosis using intestinal organoids**

10:30 - 10:52

*Speaker:* Francois Vermeulen, BE**Relations between organoid swelling and long term clinical outcomes**

10:52 - 11:14

*Speaker:* Danya Muilwijk, NL**2D intestinal organoids for personalized therapy in cystic fibrosis- A performance comparison to donor-matched nasal cells**

11:14 - 11:36

*Speaker:* Liron Birimberg-Schwartz, IL**CFTR function measurements in primary airway cell cultures of individuals with cystic fibrosis**

11:36 - 12:00

*Speaker:* Iwona Pranke, FR*Symposium*

10:30 - 12:00

R6

**S12 - Symposium 12 - Thinking differently about the GI tract****At the end of the session, the participant will be able to:**

- To increase knowledge of the role of CFTR in the GI tract
- To be aware of the growing importance of the intestinal microbiome in the management of CF
- To gain a greater understanding of the implications of the screening and management of GI malignancies in an aging CF population

*Chair:* Frank Bodewes, NL*Chair:* Anne Munck, FR**CFTR function in the gut - pathophysiology**

10:30 - 10:52

*Speaker:* Anna Bertolini, NL**The intestinal microbiome - a silent player?**

10:52 - 11:14

*Speaker:* Stephanie Van Biervliet, BE**GI malignancies - an update**

11:14 - 11:36

*Speaker:* Denis Hadjiliadis, US**The effects of CFTR carriers on gastrointestinal phenotype**

11:36 - 12:00

*Speaker:* Michael Wilschanski, IL*Satellite Symposium*

12:30 - 14:00

R1

**Satellite Symposium**Please find the detailed programme of the Satellite Symposia [here](#).

*Meet the Experts*

12:45 - 13:45

**Meet the Experts***Meet the Experts*

12:45 - 13:45

**Meet the Experts - Meet the experts 2 - Remote monitoring - Evidence and practical experience**

ePoster Corner B

*Expert:* Christopher Goss, US*Expert:* Nichola MacDuff, GB*Meet the Experts*

12:45 - 13:45

**Meet the Experts - Meet the Experts 3 - Treating the ageing CF patient**

ePoster Corner C

*Expert:* Andrew Jones, GB*Expert:* Lieven Dupont, BE*Meet the Experts*

12:45 - 13:45

**Meet the Experts - Meet the Experts 1 - How to manage CFTR modulators in severe patients (FEV1**

ePoster Corner A

*Expert:* Pierre-Régis Burgel, FR*Expert:* Maarten Ploeger, NL*ECFS Tomorrow Lounge Session*

12:45 - 13:45

**Telemedicine and mental health screening online***Chair:* Janne Houben, BE*Chair:* Pavla Hodkova, CZ*Chair:* Trudy Havermans, BE*Chair:* Anna M. Georgiopoulos, US*Chair:* Edwina Landau, IL*ePoster Session*

14:00 - 15:00

**Poster Viewing 1**

P001	<b>CF-NBS start-up in Flanders (Belgium): report of first evaluation after three years</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Julie Carbonez, BE	
P002	<b>Growth, lung microbiology and structure after implementation of newborn screening in Danish cystic fibrosis patients</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Marianne Skov, DK	
P003	<b>Wide variability of approach to cystic fibrosis newborn screening across regions of Italy</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Carlo Castellani, IT	
P004	<b>Evaluation of the efficacy of newborn screening as a tool to identify cystic fibrosis in the Russian Federation</b>	14:00 - 14:00



	<i>Abstract Presenter:</i> Victoria Sherman, RU	
P006	<b>Nephrolithiasis and nephrocalcinosis in infants with cystic fibrosis: a case presentation of two swedish infants</b> <i>Abstract Presenter:</i> ELisabeth Christiansen, SE	14:00 - 14:00
P007	<b>CFTR genotypes and spermatology in cystic fibrosis patients without CBAVD</b> <i>Abstract Presenter:</i> Anna Sedova, RU	14:00 - 14:00
P008	<b>L138ins is common CFTR gene mutation in Russian infertile men</b> <i>Abstract Presenter:</i> Ekaterina Marnat, RU	14:00 - 14:00
P009	<b>Spectrum of CFTR mutations in newly diagnosed cases of cystic fibrosis through newborn screening in the Republic of North Macedonia</b> <i>Abstract Presenter:</i> Stojka Fustik, MK	14:00 - 14:00
P013	<b>Peptide modulation of COMMD1: corrector and anti-inflammatory effect in cystic fibrosis context?</b> <i>Abstract Presenter:</i> Benjamin Simonneau, FR	14:00 - 14:00
P014	<b>Proof of concept of ionocytes' CFTR content as a novel biomarker for cystic fibrosis diagnosis and follow-up</b> <i>Abstract Presenter:</i> Fabina Ciciriello, IT	14:00 - 14:00
P015	<b>Translational read-through inducing drugs: a study of toxicity in mice models and <i>in vitro</i> safety validation of the specific read-through process</b> <i>Abstract Presenter:</i> Federica Corrao, IT	14:00 - 14:00
P017	<b>Using chamber measurement of CFTR modulator effects in airway epithelial cells and its correlation to clinical effects of treatment</b> <i>Abstract Presenter:</i> Bente Aalbers, NL	14:00 - 14:00
P018	<b>People with cystic fibrosis do not show an increased interferon-response transcriptomic signature in nasal epithelial cells</b> <i>Abstract Presenter:</i> Manu Jain, US	14:00 - 14:00
P019	<b>Monocyte integrin activation as a CFTR targeted drugs evaluation test in cystic fibrosis patients: preliminary analysis</b> <i>Abstract Presenter:</i> Jessica Conti, IT	14:00 - 14:00
P020	<b>Evaluation of TMEM16A as a modifier of the cystic fibrosis lung phenotype utilising cystic fibrosis patient-specific human-induced pluripotent stem cells</b> <i>Abstract Presenter:</i> Mark-Christian Jaboreck, DE	14:00 - 14:00
P021	<b>A novel gene delivery approach for CRISPR-Cas9-mediated permanent CFTR correction</b> <i>Abstract Presenter:</i> Jim Hu, CA	14:00 - 14:00
P022	<b>hCFTRdelR expression and correction of human cystic fibrosis airway epithelia increase with increasing SP-101 and doxorubicin doses</b> <i>Abstract Presenter:</i> Katherine Excoffon, US	14:00 - 14:00

P023	<b>High-resolution imaging reveals impaired lung development in a mouse model of cystic fibrosis-like lung disease</b> <i>Abstract Presenter:</i> Pinelopi Anagnostopoulou, CH	14:00 - 14:00
P024	<b>Patient-derived organoids as a model for treatment diagnosis in cystic fibrosis - combinatory treatment with read-through agent, correctors and potentiator on rare mutations</b> <i>Abstract Presenter:</i> Johanna Pott, NL	14:00 - 14:00
P025	<b>Assessment of CFTR modulator combinations in rectal organoids from F508del homozygous patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Senne Cuyx, BE	14:00 - 14:00
P026	<b>Therotyping of the CFTR variant G85E in trans with the complex allele A1006E+V562I using rectal organoids</b> <i>Abstract Presenter:</i> Jessica Conti, IT	14:00 - 14:00
P027	<b>Effects of ivacaftor therapy confirm the results of therotyping using rectal and nasal epithelial cells of a cystic fibrosis patient carrying the ultra-rare CFTR genotype W57G (c.169T&gt;G) / A234D (c.701C&gt;A)</b> <i>Abstract Presenter:</i> Jessica Conti, IT	14:00 - 14:00
P028	<b>Antisense oligonucleotide splicing modulation as a novel cystic fibrosis therapeutic approach for the W1282X nonsense mutation</b> <i>Abstract Presenter:</i> Yifat Oren, IL	14:00 - 14:00
P029	<b>Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation</b> <i>Abstract Presenter:</i> Yifat Oren, IL	14:00 - 14:00
P030	<b>Effect of CFTR modulators on lung function, body mass index, and <i>Pseudomonas aeruginosa</i> status in adolescents with cystic fibrosis - one-year follow-up</b> <i>Abstract Presenter:</i> Marina Praprotnik, SI	14:00 - 14:00
P031	<b>Impact of the elexacaftor/tezacaftor/ivacaftor combination regimen on lung function in adults with cystic fibrosis: more than just FEV<sub>1</sub></b> <i>Abstract Presenter:</i> Doris Deninghoff, DE	14:00 - 14:00
P032	<b>Sweat chloride values in cystic fibrosis patients on elexacaftor/texacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Nadia Mazzoni, IT	14:00 - 14:00
P033	<b>Anti-inflammatory effects of Kaftrio in adults with cystic fibrosis heterozygous for F508del-CFTR</b> <i>Abstract Presenter:</i> Heledd Jarosz-Griffiths, GB	14:00 - 14:00
P034	<b>Long-term elexacaftor/tezacaftor/ivacaftor CFTR modulation significantly increases lung function and peak power output in people with cystic fibrosis</b> <i>Abstract Presenter:</i> Barlo Hillen, DE	14:00 - 14:00
P035	<b>Elexacaftor/tezacaftor/ivacaftor improves very quickly FEV<sub>1</sub> and 6MWT very quickly in patients with cystic fibrosis and</b>	14:00 - 14:00

	<b>severe airflow obstruction</b> <i>Abstract Presenter:</i> Laurent MELY, FR	
P036	<b>Exercise performance before and after introduction of elexacaftor/tezacaftor/ivacaftor (Kaftrio) in Scottish children with cystic fibrosis: a two-centre retrospective study</b> <i>Abstract Presenter:</i> Paul D Burns, GB	14:00 - 14:00
P037	<b>Improved aerobic fitness in children on CFTRm triple combination therapy</b> <i>Abstract Presenter:</i> Uros Krivec, SI	14:00 - 14:00
P038	<b>ELX/TEZ/IVA discontinuation is more common in an older population</b> <i>Abstract Presenter:</i> Karuna Sapru, GB	14:00 - 14:00
P039	<b>Changes to clinical well-being following initiation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis - single-centre experience</b> <i>Abstract Presenter:</i> Amanda McGrath, GB	14:00 - 14:00
P040	<b>Implementation and preliminary experiences of the HERO-2 real-world research study in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Cynthia Brown, US	14:00 - 14:00
P041	<b>Clinical assessment plan for initiation and follow-up of treatment with elexacaftor/tezacaftor/ivacaftor in the danish cystic fibrosis population</b> <i>Abstract Presenter:</i> Christian Leo-Hansen, DK	14:00 - 14:00
P042	<b>The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis</b> <i>Abstract Presenter:</i> Sarah Allgood, US	14:00 - 14:00
P043	<b>Significant reduction in abdominal symptoms assessed with the CFAbd-Score over 6 months of elexacaftor/tezacaftor/ivacaftor - follow-up results from Irish and British cystic fibrosis patients (RECOVER study)</b> <i>Abstract Presenter:</i> Jochen G. Mainz, DE	14:00 - 14:00
P044	<b>Treatment benefits of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying non-F508del mutations</b> <i>Abstract Presenter:</i> Galit Livnat, IL	14:00 - 14:00
P045	<b>The impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on health outcomes in the setting of severe lung disease due to cystic fibrosis</b> <i>Abstract Presenter:</i> Sanja Stanojevic, CA	14:00 - 14:00
P046	<b>The effectiveness of CFTR modulators in people with cystic fibrosis and rare mutations - a real-world study</b> <i>Abstract Presenter:</i> Sofia Hanger, GB	14:00 - 14:00
P047	<b>Selection of CFTR modulators for children carrying the genetic variant W1282R</b> <i>Abstract Presenter:</i> Elena Kondratyeva, RU	14:00 - 14:00
P048	<b>Continuous glucose monitoring in people with cystic fibrosis highlights different glucose tolerance abnormalities</b>	14:00 - 14:00

	<b>according to pancreatic exocrine status.</b> <i>Abstract Presenter:</i> Luc RAKOTOARISOA, FR	
P049	<b>Question cystic fibrosis again: a refresh of the James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF)</b> <i>Abstract Presenter:</i> Nicola Rowbotham, GB	14:00 - 14:00
P050	<b>Writing <i>with</i> patients, <i>for</i> patients: co-creation of a cystic fibrosis plain language glossary</b> <i>Abstract Presenter:</i> Kate Hayes, GB	14:00 - 14:00
P051	<b>Improved opportunities for trial participation via the Dutch CF Trial Consortium</b> <i>Abstract Presenter:</i> Ilonka Paalvast, NL	14:00 - 14:00
P052	<b>Introduction of an innovative 'pill swallowing school' in a cystic fibrosis paediatric population within a tertiary centre</b> <i>Abstract Presenter:</i> Rachel Rowley, GB	14:00 - 14:00
P053	<b>A novel family-focused intervention to support physical activity among children (6-12 years) with cystic fibrosis</b> <i>Abstract Presenter:</i> Owen William Tomlinson, GB	14:00 - 14:00
P054	<b>Severity of COVID-19 infection in cystic fibrosis patients compared to the general population</b> <i>Abstract Presenter:</i> Chiara Rosazza, IT	14:00 - 14:00
P055	<b>The impact of virtual care on cystic fibrosis disease progression - a prospective multicentre study in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Jakob Medbo, SE	14:00 - 14:00
P056	<b>Acute pulmonary exacerbation markedly weakens beneficial effect of elexacaftor/tezacaftor/ivacaftor on systemic endothelial dysfunction in cystic fibrosis - a single case study</b> <i>Abstract Presenter:</i> Barbara Salobir, SI	14:00 - 14:00
P057	<b>Monitoring individualised CFTR modulating therapy in an adolescent with cystic fibrosis homozygous for the G85E CFTR variant using <i>in vitro</i> and <i>in vivo</i> methods</b> <i>Abstract Presenter:</i> Niklas Ziegahn, DE	14:00 - 14:00
P058	<b>Resolution of chronic pneumothorax in an adult patient with severe cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Barbara Messori, IT	14:00 - 14:00
P059	<b>Association of <i>Pseudomonas aeruginosa</i> infection stage with lung function trajectory in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Margaret Rosenfeld, US	14:00 - 14:00
P060	<b>Factors associated with pulmonary functions of cystic fibrosis patients in the National Cystic Fibrosis Patient Registry: a retrospective cohort study</b> <i>Abstract Presenter:</i> Nazan Cobanoglu, TR	14:00 - 14:00
P061	<b>Low FEV<sub>1</sub> performance in the 30-34 years of age cohort in Norway: utilising Registry data in the search for causes</b> <i>Abstract Presenter:</i> Audun OS, NO	14:00 - 14:00

P062	<b>An international survey: understanding the health and perspectives of people with cystic fibrosis (CF) not benefitting from CFTR modulators</b> <i>Abstract Presenter:</i> Jennifer Taylor-Cousar, US	14:00 - 14:00
P063	<b>Physiotherapy data for the UK cystic fibrosis Registry - review and re-launch</b> <i>Abstract Presenter:</i> Lisa Morrison, GB	14:00 - 14:00
P064	<b>Iron deficiency in cystic fibrosis: a prospective study in a modern adult cohort</b> <i>Abstract Presenter:</i> Quitterie Reynaud, FR	14:00 - 14:00
P065	<b>Cervical cancer screening in women with cystic fibrosis: should we do more?</b> <i>Abstract Presenter:</i> Megan Hadfield, GB	14:00 - 14:00
P066	<b>Changing criteria of paediatric chronic rhinosinusitis indexation in Russian National Cystic Fibrosis Registry</b> <i>Abstract Presenter:</i> Dmitry Polyakov, RU	14:00 - 14:00
P067	<b>Main characteristics of cystic fibrosis patients: National Patient Registry of Russia (RCFPR) 2020</b> <i>Abstract Presenter:</i> Elena Kondratyeva, RU	14:00 - 14:00
P068	<b>Characteristics of genetic variants of the CFTR gene in the Russian Federation according to the 2020 Registry</b> <i>Abstract Presenter:</i> Anna Voronkova, RU	14:00 - 14:00
P069	<b>Patient-reported outcome measures in children with cystic fibrosis</b>	14:00 - 14:00
P070	<b>Harnessing electronic health records to enhance observational research in cystic fibrosis</b> <i>Abstract Presenter:</i> Nicole Filipow, GB	14:00 - 14:00
P071	<b>The characterisation of a patient cohort that had home spirometry devices and opted into sharing their data with the US Cystic Fibrosis Foundation</b> <i>Abstract Presenter:</i> Alexander Elbert, US	14:00 - 14:00
P072	<b>SARS Cov2 infection in patients with cystic fibrosis (CF) - a single centre experience</b> <i>Abstract Presenter:</i> Ani Vidoevska, MK	14:00 - 14:00
P073	<b>Observed impact on admissions during the COVID-19 pandemic of paediatric cystic fibrosis patients in a tertiary hospital setting</b> <i>Abstract Presenter:</i> Sara Warraich, GB	14:00 - 14:00
P074	<b>Post-COVID-19 condition in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Anastasia Chernyavskaya, RU	14:00 - 14:00
P075	<b>COVID-19 vaccination uptake in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Dion-Emily Manning, GB	14:00 - 14:00
P076	<b>COVID-19 vaccination in children and adolescents with cystic fibrosis - a single centre experience</b> <i>Abstract Presenter:</i> ALEKSANDRA ZVER, SI	14:00 - 14:00

P077	<b>Vaccination of patients with cystic fibrosis during the COVID-19 pandemic in Croatia</b> <i>Abstract Presenter:</i> Ivona Markelić, HR	14:00 - 14:00
P078	<b>Adverse effects of Kaftrio in an adult cystic fibrosis clinic</b> <i>Abstract Presenter:</i> Douglas McCabe, GB	14:00 - 14:00
P079	<b>Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation</b> <i>Abstract Presenter:</i> Eef Vanderhelst, BE	14:00 - 14:00
P080	<b>Real-world experience of patient outcomes following one year of elexacaftor/tezacaftor/ivacaftor treatment at a single adult cystic fibrosis centre</b> <i>Abstract Presenter:</i> Ellen Shiner, GB	14:00 - 14:00
P081	<b>Adverse drug reactions linked to prolonged use of Kaftrio</b> <i>Abstract Presenter:</i> Michael Kevin Dooney, GB	14:00 - 14:00
P082	<b>Reduced dose Kaftrio can significantly improve respiratory health for those intolerant of the recommended dosing schedule</b> <i>Abstract Presenter:</i> Michael Kevin Dooney, GB	14:00 - 14:00
P083	<b>Decreased respiratory burst in circulating neutrophils after initiation of CFTR modulator therapy in cystic fibrosis patients with chronic lung infections</b> <i>Abstract Presenter:</i> Peter Østrup Jensen, DK	14:00 - 14:00
P084	<b>Counteracting inflammation triggered by <i>P. aeruginosa</i>-activated lung-infiltrating Th1/17 cells: a novel approach for precision medicine in cystic fibrosis</b> <i>Abstract Presenter:</i> Moira Paroni, IT	14:00 - 14:00
P085	<b>Evaluation of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and mean platelet volume in cystic fibrosis (CF) during exacerbation</b> <i>Abstract Presenter:</i> Tugba Sismanlar Eyuboglua, TR	14:00 - 14:00
P086	<b>Serum levels of alpha calcitonin gene-related peptide and vasoactive intestinal peptide as predictors of exacerbation in cystic fibrosis</b> <i>Abstract Presenter:</i> Maha Al-Keilani, JO	14:00 - 14:00
P087	<b>CTN - Lung Clearance Index core facility: quality improvement exercise</b> <i>Abstract Presenter:</i> Clare Saunders, GB	14:00 - 14:00
P088	<b>Ventilation inhomogeneity in patients with cystic fibrosis and pancreatic sufficiency and insufficiency</b> <i>Abstract Presenter:</i> Oded Breuer, IL	14:00 - 14:00
P089	<b>Ventilation heterogeneity in adult patients with cystic fibrosis (CF)</b> <i>Abstract Presenter:</i> Alexander Chernyak, RU	14:00 - 14:00
P090	<b>Comparison of multiple breath washout and particles in exhaled air for assessment of small airway function in</b>	14:00 - 14:00

**children with cystic fibrosis***Abstract Presenter:* Annelies M. Zwitserloot, NL

- |      |  |               |
|------|--|---------------|
| P091 | <b>Correlation of lung function using forced oscillation technique with spirometry in children aged 4-18 years with cystic fibrosis (CF)</b><br><i>Abstract Presenter:</i> SACHIN SINGH, IN  | 14:00 - 14:00 |
| P092 | <b>Exploring the association between hand grip strength (HGS) and lung function (FEV<sub>1</sub>%) in cystic fibrosis: does HGS offer an insight into pulmonary function?</b><br><i>Abstract Presenter:</i> Matthew Taylor, GB                       | 14:00 - 14:00 |
| P093 | <b>The effect of probiotic administration on glucose metabolism and metabolomics in cystic fibrosis patients</b><br><i>Abstract Presenter:</i> Michal Gur,   | 14:00 - 14:00 |
| P094 | <b>Randomised controlled trial of humanoid robot-based distraction for invasive nursing procedures in children with cystic fibrosis: preliminary results</b><br><i>Abstract Presenter:</i> Sergio Bella, IT  | 14:00 - 14:00 |
| P095 | <b>Effect of hypertonic saline therapy on Lung Clearance Index in preschool children with cystic fibrosis</b><br><i>Abstract Presenter:</i> Almala Pinar Ergenekon, TR   | 14:00 - 14:00 |
| P096 | <b>Tolerability of tigerase (dornase alfa) in children</b><br><i>Abstract Presenter:</i> Vera Shadrina, RU   | 14:00 - 14:00 |
| P097 | <b>Evaluation of the inhaled mannitol tolerance test in children with cystic fibrosis</b><br><i>Abstract Presenter:</i> Vera Shadrina, RU  | 14:00 - 14:00 |
| P098 | <b>The use of mucolytic therapy in cystic fibrosis in the Russian Federation</b><br><i>Abstract Presenter:</i> Vera Shadrina, RU   | 14:00 - 14:00 |
| P099 | <b>Inhaled tobramycin solution hypersensitivity in patients with cystic fibrosis at the Centre for Cystic Fibrosis, Institute for Pulmonary Diseases in Children in North Macedonia</b><br><i>Abstract Presenter:</i> Marija Atanasova Nadzinska, MK | 14:00 - 14:00 |
| P100 | <b>Beneficial effects and safety of omalizumab during pregnancy in a patient with cystic fibrosis</b><br><i>Abstract Presenter:</i> Barbara Messori, IT  | 14:00 - 14:00 |
| P101 | <b>Microbiological surveillance in cystic fibrosis - an emerging multifactorial challenge</b><br><i>Abstract Presenter:</i> Peter Barry, GB  | 14:00 - 14:00 |
| P102 | <b>Prevalence of sensitisation to common inhaled allergens in a Belgian adult cystic fibrosis population and its impact on respiratory outcomes</b><br><i>Abstract Presenter:</i> Henri Marissiaux, BE   | 14:00 - 14:00 |
| P103 | <b>Evaluation of patient opinion about the current and future pharmacy service for an adult cystic fibrosis clinic</b><br><i>Abstract Presenter:</i> Douglas McCabe, GB  | 14:00 - 14:00 |

P104	<b>Exploring the value of annual chest radiographs in people with cystic fibrosis: an observational study from a single UK centre</b> <i>Abstract Presenter:</i> Christopher Stovin, GB	14:00 - 14:00
P105	<b>Home spirometry is reliable and of consistent quality in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Siobhan Carr, GB	14:00 - 14:00
P106	<b>Upper airway disease in adults with cystic fibrosis: a cross-sectional study</b> <i>Abstract Presenter:</i> Saartje Uyttebroek, BE	14:00 - 14:00
P107	<b>Coexistence of cystic fibrosis and metabolic disease: is this a related or coincidental condition?</b> <i>Abstract Presenter:</i> Halime Nayır Buyuksahin, TR	14:00 - 14:00
P108	<b>Impact of improved nontuberculous mycobacterial culture surveillance strategy in an adult cystic fibrosis cohort</b> <i>Abstract Presenter:</i> Natalie Lorent, BE	14:00 - 14:00
P109	<b>Evaluation of early lung disease in school-age children with cystic fibrosis - a preliminary report</b> <i>Abstract Presenter:</i> Katarzyna Walicka-Serzysko,	14:00 - 14:00
P110	<b>Trends in asthma diagnosis and usage of asthma medications in children with cystic fibrosis - are we looking for it?</b> <i>Abstract Presenter:</i> Anirban Maitra, GB	14:00 - 14:00
P111	<b>Atopy and cystic fibrosis: characterisation of a paediatric portuguese population</b> <i>Abstract Presenter:</i> Susana Castanhinha, PT	14:00 - 14:00

*ePoster Session*

14:00 - 15:00

**ePoster Session 1 - What have we learned from the psychosocial impacts of COVID-19?**

## ePoster Corner A

*Leader:* Trudy Havermans, BE*Leader:* Kathryn Braisdell, GB

EPS1.01	<b>Home spirometry and virtual visits in children with cystic fibrosis - the child's perspective</b> <i>Abstract Presenter:</i> Frida Olofsson, SE	14:00 - 14:06
EPS1.02	<b>Long-term psychological impact of COVID-19 on adult patients with cystic fibrosis, including transplanted patients</b> <i>Abstract Presenter:</i> Trudy Havermans, BE	14:06 - 14:12
EPS1.03	<b>The impact of the COVID-19 lockdown and introduction of precision medication Symkevi and Orkambi on cystic fibrosis patients at Sheffield Children's NHS Foundation Trust, UK (SCFT)</b> <i>Abstract Presenter:</i> Kathryn Braisdell, GB	14:12 - 14:18
EPS1.04	<b>Sleep disturbances in children with cystic fibrosis at the beginning and in the first year of the COVID-19 pandemic</b> <i>Abstract Presenter:</i> Tugba Sismanlar Eyuboglu, TR	14:18 - 14:24



EPS1.05	<b>Impact of COVID-19 on mental health among people with cystic fibrosis</b> <i>Abstract Presenter:</i> Elpis Hatziagorou, GR	14:24 - 14:30
EPS1.06	<b>Evolution of psychological distress during progression of the COVID-19 pandemic in adults with cystic fibrosis</b> <i>Abstract Presenter:</i> Federico Cresta, IT	14:30 - 14:36
EPS1.07	<b>Parental experiences of face-to-face versus virtual cystic fibrosis clinics during the COVID-19 pandemic: questionnaire study</b> <i>Abstract Presenter:</i> Kieren James Lock, GB	14:36 - 14:42
EPS1.08	<b>Telemedicine clinics for people with cystic fibrosis (CF): experiences 18 months on</b> <i>Abstract Presenter:</i> Muhammad Haris Mir, GB	14:42 - 14:48
EPS1.09	<b>Exploring associations and indirect effects between mindfulness, psychological flexibility, and well-being in adults with cystic fibrosis: informing future interventions</b> <i>Abstract Presenter:</i> Sophia Kauser, GB	14:48 - 14:54
EPS1.10	<b>Easy Medicines for Burden Reduction And Care Enhancement (EMBRACE): Exploring the views of adults with cystic fibrosis on the current nebulised medicines supply process using homecare deliveries in two UK centres</b> <i>Abstract Presenter:</i> Aoife Lynam, GB	14:54 - 15:00

*ePoster Session*  
14:00 - 15:00

#### **ePoster Sessions**

*ePoster Session*  
14:00 - 15:00

#### **ePoster Session 2 - Did some good come from COVID-19? The lasting value of remote treatment**

ePoster Corner B

*Leader:* Brenda Button, AU

*Leader:* Donald Urquhart, GB

EPS2.01	<b>Home monitoring of airway clearance treatments (ACTs) in children and young people with cystic fibrosis</b> <i>Abstract Presenter:</i> Emma Raywood, GB	14:00 - 14:06
EPS2.02	<b>Comparison of FEV<sub>1</sub> on a remote spirometry device with hospital software in an adult cystic fibrosis cohort</b> <i>Abstract Presenter:</i> Paul Wilson, GB	14:06 - 14:12
EPS2.03	<b>A service evaluation of 'CF THRIVE': an online, student-led group for children with cystic fibrosis</b> <i>Abstract Presenter:</i> Madeline Pilbury, GB	14:12 - 14:18
EPS2.04	<b>Is tele-physiotherapy as effective as home-visit-guided physiotherapy among children with cystic fibrosis?</b> <i>Abstract Presenter:</i> Pauline Peftoulidou, GR	14:18 - 14:24
EPS2.05	<b>Use of BEAM to enhance participation in exercise</b> <i>Abstract Presenter:</i> Aimee Johnson, GB	14:24 - 14:30

EPS2.06	<b>"It's good to talk" - development of a virtual international physiotherapy discussion forum</b> <i>Abstract Presenter:</i> Gemma E Stanford, GB	14:30 - 14:36
EPS2.07	<b>International collaboration and development of a cystic fibrosis physiotherapy-specific telehealth toolkit</b> <i>Abstract Presenter:</i> Lisa Morrison, GB	14:36 - 14:42
EPS2.08	<b>Patient and parent experience of a virtual physiotherapy clinic in children with cystic fibrosis - a pilot study</b> <i>Abstract Presenter:</i> Linn Hoel, SE	14:42 - 14:48
EPS2.09	<b>Feasibility and acceptability of establishing virtual exercise classes for cystic fibrosis (CF) patients</b> <i>Abstract Presenter:</i> Ellen Shiner, GB	14:48 - 14:54
EPS2.10	<b>Exercise testing and training in cystic fibrosis clinics in the United Kingdom: a ten-year update</b> <i>Abstract Presenter:</i> Owen William Tomlinson, GB	14:54 - 15:00

*ePoster Session*

14:00 - 15:00

**ePoster Session 3 - Pathogenesis and treatment of CF pathogens**

ePoster Corner C

*Leader:* Deirdre Gilpin, GB*Leader:* Edith Zemanick, US

EPS3.01	<b>Preliminary results of an ongoing study, which determines the prevalence and possible impact of mucoid <i>Staphylococcus aureus</i> on lung disease of people with cystic fibrosis</b> <i>Abstract Presenter:</i> Christine Rumpf, DE	14:00 - 14:06
EPS3.02	<b>Deciphering the adaptive evolution of successful <i>Pseudomonas aeruginosa</i> lineages within persistent bacterial infections</b> <i>Abstract Presenter:</i> Akbar Espallat, DK	14:06 - 14:12
EPS3.03	<b>Using patient-derived airway models to study <i>Pseudomonas aeruginosa</i> colonisation and infection</b> <i>Abstract Presenter:</i> Signe Lolle, DK	14:12 - 14:18
EPS3.04	<b>Does <i>Achromobacter xylosoxidans</i> have specific characteristics that could contribute to its emergence in cystic fibrosis?</b> <i>Abstract Presenter:</i> Pauline Sorlin, FR	14:18 - 14:24
EPS3.05	<b>Induced levofloxacin resistance persists in evolved lineages of <i>Pseudomonas aeruginosa</i> isolates from people with cystic fibrosis after exposure to other inhaled antibiotics</b> <i>Abstract Presenter:</i> Callum Matthew Sloan, GB	14:24 - 14:30
EPS3.06	<b>Isolation and characterisation of nebulised phage for treatment of chronic <i>Pseudomonas aeruginosa</i> (Pa) pulmonary infections in cystic fibrosis (CF) patients</b> <i>Abstract Presenter:</i> Maya Kahan-Hanum, IL	14:30 - 14:36

EPS3.07	<b>Exploring the therapeutic potential of iminosugars as antibacterial and antibiofilm agents in the treatment of cystic fibrosis lung disease infections</b> <i>Abstract Presenter:</i> Anna Esposito, IT	14:36 - 14:42
EPS3.08	<b>Inhaled powder tobramycin (TIP): cyclical versus continuous treatment: iBEST Study</b> <i>Abstract Presenter:</i> Aya Alkhatib, GB	14:42 - 14:48
EPS3.09	<b>Methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA) with inoculum-related reduced susceptibility to cefazolin (CZ) and piperacillin-tazobactam (TZP) in persons with cystic fibrosis (pwCF)</b> <i>Abstract Presenter:</i> Julianna Svishchuk, CA	14:48 - 14:54
EPS3.10	<b>Opportunistic bacterial pathogens: potential transmissions between the patients and their domestic environment</b> <i>Abstract Presenter:</i> Quentin Menetrey, FR	14:54 - 15:00

*ECFS Tomorrow Lounge Session*

14:00 - 15:00

**Nutrition: Future role of the dietitian in CF***Chair:* Sarah Collins, GB*Chair:* Elizabeth Owen, GB*Workshop*

15:00 - 16:30

R1

**WS01 - WS01: Treatment of respiratory infection in cystic fibrosis***Chair:* Michal Shteinberg, IL*Chair:* Michael Tunney, GB

WS01.01	<b>Antipseudomonal treatment decisions during cystic fibrosis exacerbation management</b> <i>Abstract Presenter:</i> Donald R. VanDevanter, US	15:00 - 15:15
WS01.02	<b>Trends and outcomes of long-term inhaled antimicrobial treatment in people with cystic fibrosis without chronic <i>Pseudomonas aeruginosa</i> infection: an ECFS data analysis</b> <i>Abstract Presenter:</i> Michal Shteinberg, IL	15:15 - 15:30
WS01.03	<b>CFTR modulators impact antibiotic susceptibility of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i></b> <i>Abstract Presenter:</i> Cristina Cigana, IT	15:30 - 15:45
WS01.04	<b>A new weapon against <i>Mycobacterium abscessus</i></b> <i>Abstract Presenter:</i> Giulia Degiacomi, IT	15:45 - 16:00
WS01.05	<b>Combination of the lytic bacteriophage NP3 with ciprofloxacin has a synergistic effect on biofilms of cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates</b> <i>Abstract Presenter:</i> Oana Ciofu, DK	16:00 - 16:15
WS01.06	<b>The impact of Orkambi on respiratory cystic fibrosis pathogens</b> <i>Abstract Presenter:</i> Mahasin Al Shakirchi, SE	16:15 - 16:30

## Workshop

15:00 - 16:30

R2

**WS02 - WS02: Digestive and liver disease upon elexacaftor/tezacaftor/ivacaftor therapy**

Chair: Michael Wilschanski, IL

Chair: Jaroslaw Walkowiak, PL

- |         |  |               |
|---------|--|---------------|
| WS02.01 | <b>Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/tvacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK</b><br><i>Abstract Presenter:</i> Jochen G. Mainz, DE | 15:00 - 15:15 |
| WS02.02 | <b>MRI metrics of small bowel water in cystic fibrosis (CF) before and after elexacaftor/tezacaftor/ivacaftor: first results from the GIFT-CF3 Study</b><br><i>Abstract Presenter:</i> Christabella Ng, GB   | 15:15 - 15:30 |
| WS02.03 | <b>Investigating changes in liver function tests across the first year of elexacaftor/tezacaftor/ivacaftor therapy</b><br><i>Abstract Presenter:</i> Nicola Robinson, GB   | 15:30 - 15:45 |
| WS02.04 | <b>Liver function test abnormalities in cystic fibrosis patients commenced on ELX/TEZ/IVA in a large adult cystic fibrosis centre over 12 months</b><br><i>Abstract Presenter:</i> Daniel Tewkesbury, GB   | 15:45 - 16:00 |
| WS02.05 | <b>The use of elexacaftor/tezacaftor/ivacaftor in adult patients with cystic fibrosis and established liver cirrhosis: a case series</b><br><i>Abstract Presenter:</i> James Sun, GB   | 16:00 - 16:15 |
| WS02.06 | <b>Can liver biopsy guide the management of deranged liver function tests in liver transplant recipients receiving Kaftrio?</b><br><i>Abstract Presenter:</i> Phaedra Tachtatzis, GB   | 16:15 - 16:30 |

## Workshop

15:00 - 16:30

R3

**WS03 - WS03: Modulator therapies: what impact are they having on my life?**

Chair: Edwina Landau, IL

Chair: Majda Oštir, SI

- |         |  |               |
|---------|--|---------------|
| WS03.01 | <b>Impact of Trikafta on PHQ-9 and GAD-7 scores</b><br><i>Abstract Presenter:</i> Heather Bruschwein, US   | 15:00 - 15:15 |
| WS03.02 | <b>Understanding beliefs about elexacaftor/tezacaftor/ivacaftor (ETI) therapy in adults living with cystic fibrosis</b><br><i>Abstract Presenter:</i> Jamie Duckers, GB        | 15:15 - 15:30 |
| WS03.03 | <b>Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA</b><br><i>Abstract Presenter:</i> Trudy Havermans, BE   | 15:30 - 15:45 |
| WS03.04 | <b>Psychosocial outcomes from annual review - a comparison of young people prescribed CFTR medication and those who were not</b><br><i>Abstract Presenter:</i> Steve Jones, GB | 15:45 - 16:00 |
| WS03.05 | <b>Proportion days covered: what does it tell us about adherence to Kaftrio and Kalydeco?</b>  | 16:00 - 16:15 |

*Abstract Presenter:* Amanda Bevan, GB

WS03.06      **Does the use of modulator therapies in adults with cystic fibrosis have a long-term impact on the requirement for intravenous antibiotics**      16:15 - 16:30

*Abstract Presenter:* Sharon Geoghegan, GB

#### Workshop

15:00 - 16:30

R4

#### **WS04 - WS04: There is more to CF than the lung**

*Chair:* Peter Barry, GB

*Chair:* Dorota Sands, PL

WS04.01      **Do adults with Cystic Fibrosis-Related Diabetes on insulin treatment benefit from using flash glucose monitoring?**      15:00 - 15:15

*Abstract Presenter:* Harbinder Sunsoa, GB

WS04.02      **Clinical impact of pathogenic CFTR mutations in paediatric-onset pancreatitis (preliminary analysis from the APPLE study)**      15:15 - 15:30

*Abstract Presenter:* Márk Félix Juhász, HU

WS04.03      **Pulmonary impacts of the long-term use of proton pump inhibitors to potentialise the effect of pancreatic extracts in children with cystic fibrosis**      15:30 - 15:45

*Abstract Presenter:* Sahar Awada, FR

WS04.04      **Impact of planned versus unplanned pregnancy in people with cystic fibrosis**      15:45 - 16:00

*Abstract Presenter:* Raksha Jain, US

WS04.05      **What is the scope for colorectal cancer screening in cystic fibrosis? Ten years of experience at a UK cystic fibrosis centre**      16:00 - 16:15

*Abstract Presenter:* Karuna Sapru, GB

WS04.06      **Neoplastic disease and treatment in cystic fibrosis (CF): a comprehensive single centre case series**      16:15 - 16:30

*Abstract Presenter:* Alan Anderson, GB

#### Symposium

15:00 - 16:30

R5

#### **SS01 - Special Symposium - Making time for exercise and physical activity**

**At the end of the session, the participant will be able to:**

- Describe benefits of exercise and physical activity further to latest data from ACTIVATE-CF study and the updated Cochrane review
- Evaluate exercise recommendations based on considerations of age, disease severity, patient preference, barriers to exercise
- Summarize the evidence that exercise may replace chest physiotherapy as airway clearance therapy (ACT)
- Discuss different approaches to design studies to examine whether exercise can replace ACT

*Chair:* Helge Hebestreit, DE

*Chair:* Marcella Burghard, NL

**ACTIVATE-CF and Updated Cochrane Review: New perspectives on the benefits of exercise and physical activity**      15:00 - 15:22

*Speaker:* Thomas Radtke, CH

	<b>Exercise recommendations are not ‘one size, fits all’</b>	15:22 - 15:44
	<i>Speaker:</i> Mathieu Gruet, FR	
	<b>Exercise as Airway Clearance - Perspectives of the CF community on exercise as replacement for chest physiotherapy</b>	15:44 - 16:06
	<i>Speaker:</i> Nicola Rowbotham, GB	
	<b>Exercise as Airway Clearance - Routes to designing studies to examine whether exercise can replace ACT</b>	16:06 - 16:30
	<i>Speaker:</i> Zoe Saynor, GB	
 <i>Workshop</i>		
15:00 - 16:30		R6
<b>WS05 - WS05: Understanding the impact of CFTR in epithelial biology</b>		
<i>Chair:</i> Carlos M Farinha, PT		
<i>Chair:</i> Nicoletta Pedemonte, IT		
WS05.01	<b>Characterisation of the molecular mechanisms underlying PI3Ky-dependent CFTR stability at the plasma membrane</b>	15:00 - 15:15
	<i>Abstract Presenter:</i> Alessandra Murabito, IT	
WS05.02	<b>CFTR rescue by lumacaftor (VX-809) induces an extensive reorganisation of mitochondria in the cystic fibrosis bronchial epithelium</b>	15:15 - 15:30
	<i>Abstract Presenter:</i> Nicoletta Pedemonte, IT	
WS05.03	<b>Metabolomic impact of the restoration of CFTR activity in the respiratory epithelium</b>	15:30 - 15:45
	<i>Abstract Presenter:</i> Emmanuelle Bardin, FR	
WS05.04	<b>SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells</b>	15:45 - 16:00
	<i>Abstract Presenter:</i> Virginia Lotti, IT	
WS05.05	<b>Proximity profiling of the CFTR interaction landscape in response to Orkambi</b>	16:00 - 16:15
	<i>Abstract Presenter:</i> Melissa Iazzi, CA	
WS05.06	<b>Novel high-throughput screening tool for monitoring CFTR levels and localisation in cytoplasm membrane with luminescent peptide tag</b>	16:15 - 16:30
	<i>Abstract Presenter:</i> Martin Ondra, CZ	
 <i>Workshop</i>		
17:00 - 18:30		R1
<b>WS06 - WS06: Expanding the use and knowledge on CFTR modulators</b>		
<i>Chair:</i> Silke van Koningsbruggen-Rietschel, DE		
<i>Chair:</i> Damian G Downey, GB		
WS06.01	<b>HIT-CF organoid screen with ELX-02 for people with CFTR nonsense mutations as a predictive tool for clinical response</b>	17:00 - 17:15
	<i>Abstract Presenter:</i> Marlou Bierlaagh, NL	
WS06.02	<b>Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in</b>	17:15 - 17:30

	<b>people with cystic fibrosis in a real-world setting - the RECOVER study</b> <i>Abstract Presenter:</i> Paul McNally, IE	
WS06.03	<b>Novel CFTR modulator combinations maximise functional rescue of G85E and N1303K in rectal organoids</b> <i>Abstract Presenter:</i> Marjolein Ensink, BE	17:30 - 17:45
WS06.04	<b>Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles</b> <i>Abstract Presenter:</i> Simon Y. Graeber, DE	17:45 - 18:00
WS06.05	<b>Trikafta-mediated bicarbonate transport correction in F508del primary cell cultures</b> <i>Abstract Presenter:</i> Agathe Lepissier, FR	18:00 - 18:15
WS06.06	<b>The cystic fibrosis urine bicarbonate challenge test</b> <i>Abstract Presenter:</i> Peder Berg, DK	18:15 - 18:30
<i>Workshop</i> 17:00 - 18:30		R2
<b>WS07 - WS07: Factors influencing lung function and survival</b>		
<i>Chair:</i> Clémence Martin, FR		
<i>Chair:</i> Patrick Flume, US		
WS07.01	<b>Investigating the effects of dornase alfa and hypertonic saline used in combination on lung function in people with cystic fibrosis</b> <i>Abstract Presenter:</i> Emily Granger, GB	17:00 - 17:15
WS07.02	<b>Lumacaftor/ivacaftor in people with cystic fibrosis: factors predisposing the response and impact on lung function decline</b> <i>Abstract Presenter:</i> Julie Mesinele, FR	17:15 - 17:30
WS07.03	<b>Does changing from lumacaftor/ivacaftor (Orkambi) to tezacaftor/ivacaftor + ivacaftor (Symkevi + ivacaftor) offer any clinical benefits in children with cystic fibrosis (CF)?</b> <i>Abstract Presenter:</i> Lucy Paskin, GB	17:30 - 17:45
WS07.04	<b>Electronic Home Monitoring of Children with Cystic Fibrosis To Detect and Treat Acute Pulmonary exacerbations and their effect on one-year FEV<sub>1</sub> loss</b> <i>Abstract Presenter:</i> Muruvvet Yanaz, TR	17:45 - 18:00
WS07.05	<b>Investigating the relationship between lung function decline and time to death or lung transplantation, accounting for geographical variability</b> <i>Abstract Presenter:</i> Elrozy Andrinopoulou, NL	18:00 - 18:15
WS07.06	<b>Geographical distance and survival among adult cystic fibrosis lung transplant recipients in the United States</b> <i>Abstract Presenter:</i> Shivani Patel, US	18:15 - 18:30

## Workshop

17:00 - 18:30

R3

**WS08 - WS08: What has changed in CF epidemiology and why?**

Chair: Andreas Jung, CH

Chair: Lutz Naehrlich, DE

- |         |   |               |
|---------|---|---------------|
| WS08.01 | <b>Changing epidemiology of cystic fibrosis in Europe from 2010 to 2019: data from the European Cystic Fibrosis Society Patient Registry</b><br><i>Abstract Presenter:</i> Elpis Hatziagorou, GR                                | 17:00 - 17:15 |
| WS08.02 | <b>Contemporary incidence of cystic fibrosis in Canada and the United States</b><br><i>Abstract Presenter:</i> Sanja Stanojevic, CA   | 17:15 - 17:30 |
| WS08.03 | <b>Healthcare-Associated Links in Transmission of Nontuberculous mycobacteria in People with Cystic Fibrosis (HALT NTM): a multi-centre study</b><br><i>Abstract Presenter:</i> Jane E. Gross, US                               | 17:30 - 17:45 |
| WS08.04 | <b>Real-world data demonstrate clinical response in people with cystic fibrosis (pwCF) who have select residual function (RF) mutations and are treated with ivacaftor (IVA)</b><br><i>Abstract Presenter:</i> Mark Higgins, GB | 17:45 - 18:00 |
| WS08.05 | <b>Parenthood impacts short-term health outcomes in people with cystic fibrosis</b><br><i>Abstract Presenter:</i> Jennifer Taylor-Cousar, US  | 18:00 - 18:15 |
| WS08.06 | <b>Investigating associations between air pollution and the severity of cystic fibrosis in Great Britain</b><br><i>Abstract Presenter:</i> Muhammad Saleem Khan, GB   | 18:15 - 18:30 |

## Workshop

17:00 - 18:30

R4

**WS09 - WS09: Including people with CF and their families in delivering high-quality care**

Chair: Jacqueliën Noordhoek, NL

- |         |  |               |
|---------|--|---------------|
| WS09.01 | <b>Make cystic fibrosis research results accessible to all: a French initiative managed by patients and relatives</b><br><i>Abstract Presenter:</i> Estelle Ruffier, FR  | 17:00 - 17:15 |
| WS09.02 | <b>Setting up an e-learning program for male patients presenting cystic fibrosis infertility</b><br><i>Abstract Presenter:</i> Sophie Ramel, FR  | 17:15 - 17:30 |
| WS09.03 | <b>A review of patients' thoughts, feelings and priorities as evidenced in their responses to the paediatric cystic fibrosis annual review questionnaires</b><br><i>Abstract Presenter:</i> Jill Watkinson, GB | 17:30 - 17:45 |
| WS09.04 | <b>Psychometric characteristics of the CF Coping Self-Efficacy (CF-CSE) scale</b><br><i>Abstract Presenter:</i> Anna M. Georgiopoulos, US  | 17:45 - 18:00 |
| WS09.05 | <b>Using the CFHealthHub digital learning health system to optimise the nebulised medicines supply process in five UK adult cystic fibrosis (CF) centres</b>   | 18:00 - 18:15 |



<i>Abstract Presenter:</i> Sophie Dawson, GB		
WS09.06	<b>A questionnaire to gain an understanding of adherence to inhaled therapies, airway clearance and exercise since commencing the triple combination modulator in cystic fibrosis</b>	18:15 - 18:15
<i>Abstract Presenter:</i> Paul Wilson, GB		
<i>Workshop</i>		
17:00 - 18:30		R5
<b>WS10 - WS10: Physical health outcomes with or without modulator therapy</b>		
Mandy Bryon		
<i>Chair:</i> Thomas Radtke, CH		
<i>Chair:</i> Gemma E Stanford, GB		
WS10.01	<b>Impact of triple CFTR modulator therapy on airway clearance and nebuliser adherence in adults with cystic fibrosis</b>	17:00 - 17:15
<i>Abstract Presenter:</i> Louise Warnock, GB		
WS10.02	<b>People with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy demonstrate improved physical activity levels and cardiovascular fitness</b>	17:15 - 17:30
<i>Abstract Presenter:</i> Thomas Simon FitzMaurice, GB		
WS10.03	<b>Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis</b>	17:30 - 17:45
<i>Abstract Presenter:</i> Alice Midwinter, GB		
WS10.04	<b>Exploring the effects of Kaftrio on the physiotherapists' role and service provision for people with cystic fibrosis: a UK and Republic of Ireland (ROI) survey.</b>	17:45 - 18:00
<i>Abstract Presenter:</i> Orla Aisling O'Beirne, GB		
WS10.05	<b>Physical fitness and habitual physical activity in adults with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?</b>	18:00 - 18:15
<i>Abstract Presenter:</i> Wolfgang Gruber, DE		
WS10.06	<b>Adherence to nebulised medication in paediatric patients with cystic fibrosis following introduction of modulator therapy</b>	18:15 - 18:30
<i>Abstract Presenter:</i> Mostin Hu, GB		
<i>Workshop</i>		
17:00 - 18:30		R6
<b>WS11 - WS11: How much CF is it? Revisiting the dilemma of CF diagnosis</b>		
<i>Chair:</i> Carlo Castellani, IT		
<i>Chair:</i> Philippe Reix, FR		
WS11.01	<b>Divergent diagnostic assessment of cystic fibrosis and related disorders: an analysis of paediatric cases categorisation by 50 international specialists</b>	17:00 - 17:15
<i>Abstract Presenter:</i> Carlo Castellani, IT		

WS11.02	<b>Inconsistent IRT threshold values and CFTR panels in newborn screening for cystic fibrosis across the United States</b> <i>Abstract Presenter:</i> Maryann Riyadh Rehani, US	17:15 - 17:30
WS11.03	<b>Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen-positive, inconclusive diagnosis (CRMS/CFSPID)</b> <i>Abstract Presenter:</i> Magdalena Postek, PL	17:30 - 17:45
WS11.04	<b>Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis</b> <i>Abstract Presenter:</i> Steven Zhang, CA	17:45 - 18:00
WS11.05	<b>Clinical, microbiological and functional outcomes of children with inconclusive diagnosis of cystic fibrosis following newborn screening (CFSPID/CRMS)</b> <i>Abstract Presenter:</i> Thomas Perrin, FR	18:00 - 18:15
WS11.06	<b>A 14-year review of cystic fibrosis newborn screening outcomes from a UK regional laboratory</b> <i>Abstract Presenter:</i> Sarah Driscoll, GB	18:15 - 18:30

*Satellite Symposium*

19:00 - 20:30

R3

**Satellite Symposium**Please find the detailed programme of the Satellite Symposia [here](#).

**Friday, 10. June 2022***Symposium*

08:30 - 10:00

R1

**S13 - Symposium 13 - What's next for CFTR modulators?***Chair:* Nicholas Simmonds, GB*Chair:* Dorota Sands, PL**Stopping trials in CF patients on CFTR modulators** 08:30 - 08:52*Speaker:* Gwyneth Davies, GB**The value of monitoring CFTR modulator drug levels** 08:52 - 09:14*Speaker:* Martin Hug, DE**Lessons from modulator studies in people with rare residual function mutations** 09:14 - 09:36*Speaker:* Nicoletta Pedemonte, IT**Biomarkers for the personalized assessment of a therapeutic response** 09:36 - 10:00*Speaker:* Kors Van der Ent, NL*Symposium*

08:30 - 10:00

R2

**S14 - Symposium 14 - Lung transplantation - 2022 update****At the end of the session, the participant will be able to:**

- Examine the current contra-indications to lung transplant in a CF population
- Evaluate the potential role of CFTR modulators post lung transplantation
- Discuss the indications and complexities of double organ transplantation in cystic fibrosis
- Identify challenges associated with lung transplantation in the paediatric period

*Chair:* Kathleen J. Ramos, US*Chair:* Paul Aurora, GB**Contraindications to lung transplant** 08:30 - 08:52*Speaker:* Antoine Roux, FR**CFTR modulator use post lung transplantation** 08:52 - 09:14*Speaker:* Kathleen J. Ramos, US**Double organ transplantation - indications and outcomes** 09:14 - 09:36*Speaker:* Lieven Dupont, BE**Specific challenges with pediatric lung transplantation** 09:36 - 10:00*Speaker:* Paul Aurora, GB*Symposium*

08:30 - 10:00

R3

**S15 - Symposium 15 - "It's life, Jim, but not as we know it"**

At the end of the session the participants will be able to:

This symposium looks at the changing face of CF - not just because of the advent of CFTR modulators but also the gradual changes that have been happening for some time (improved survival; an aging CF population; bigger adult centres; technological improvements allowing remote monitoring and home working ; a global pandemic , a changing job market etc.)

*Chair:* Lynsay Kinnaird, GB*Chair:* Ulrike Smrekar, AT**Changing the way we think - coaching and caring for the** 08:30 - 08:52

**well CF patient.***Speaker:* Majda Oštir, SI**Changing the way we think - patient perspectives on treatment priorities**

08:52 - 09:14

*Speaker:* Jutta Bend, DE**Changing the way we think about the aging CF patient: what do we need to know?**

09:14 - 09:36

*Speaker:* Yvonne Prins, NL**Changing the way we think - Adjusting and adapting CF services**

09:36 - 10:00

*Speaker:* Charlotte Dawson, GB*Symposium*

08:30 - 10:00

R4

**S16 - Symposium 16 - Nutrition in cystic fibrosis****At the end of the session, the participant will be able to:**

- gain a greater understanding of nutritional requirements for people with CF in view of advances in medical treatments
- Explore situations when nutritional support might be needed and how it can be delivered
- Gain understanding of how different CFTR modulators influence eating habits and behaviours
- Explore changes in diet and lifestyle that people with CF have adopted in the era of CFTR modulatory therapy
- provide an update on how current apps available in Europe can support the self-management of PERT for people with CF

*Chair:* Elizabeth Owen, GB*Chair:* Dimitri Declercq, BE**There is no longer a role for nutrition support in cystic fibrosis - True**

08:30 - 08:52

*Speaker:* Darren Sills, GB**There is no longer a role for nutrition support in cystic fibrosis - False**

08:52 - 09:14

*Speaker:* Monika Mielus, PL**Impact of CFTR modulators on eating habits and behaviour (including pt perspective)**

09:14 - 09:36

*Speaker:* Sarah Collins, GB**Use of mobile applications to support self-management of PERT (look at future adaptations e.g changing enzyme requirements on modulators)**

09:36 - 10:00

*Speaker:* Mieke Boon, BE*Symposium*

08:30 - 10:00

R5

**S17 - Symposium 17 - Best of Journal of Cystic Fibrosis, Lancet Respiratory Medicine and European Respiratory Journal***Chair:* Patrick Flume, US*Chair:* Emma Grainger, GB*Chair:* Marcus Mall, DE**Introduction**

08:30 - 08:45

<b>JCF - Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X Nonsense Mutation</b>	08:45 - 09:05
<i>Speaker:</i> Batsheva Kerem, IL <i>Discussant:</i> Donald R. VanDevanter, US	
<b>ERJ - Forskolin-induced Organoid Swelling is Associated with Long-term CF Disease Progression</b>	09:05 - 09:25
<i>Speaker:</i> Danya Muilwijk, NL <i>Discussant:</i> Simon Y. Graeber, DE	
<b>LRM - The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial</b>	09:25 - 09:45
<i>Speaker:</i> Harm Tiddens, NL <i>Discussant:</i> Margaret Rosenfeld, US	
<b>Editors' topic</b>	09:45 - 10:00

*Symposium*

08:30 - 10:00

R6

**S18 - Symposium 18 - Enhancing CF registry studies through linkage with other data sources****At the end of the session, the participant will be able to:**

- Demonstrate knowledge of the challenges and opportunities of linking CF registries with other data sources.
- Discuss data on environmental factors in lung function decline.
- Recognize how insight from the patient voice can be integrated into CF registries.
- Describe the challenges and opportunities of linking national CF registries for the purposes of collecting unified data.

*Chair:* Vincent Gilmans, NL*Chair:* Uros Krivec, SI

<b>France (Lyon): "Linkage between the French CF Registry and health insurance reimbursement data"</b>	08:30 - 08:52
<i>Speaker:</i> Isabelle Durieu, FR	
<b>US/Netherlands: "Linking US registry data with geospatial data: longitudinal associations between environmental factors and lung function decline."</b>	08:52 - 09:14
<i>Speaker:</i> Elrozy Andrinopoulou, NL	
<b>UK: "Context is key - weaving patient voice and wider health system insight into the UK CF Registry".</b>	09:14 - 09:36
<i>Speaker:</i> Rebecca Cosgriff, GB	
<b>Switzerland/European CF Registry: "Building a COVID-CF registry through linkage between national registries."</b>	09:36 - 10:00
<i>Speaker:</i> Andreas Jung, CH	

*ECFS Tomorrow Lounge Session*

10:00 - 10:30

**CF plain language glossary launch**

## Symposium

10:30 - 12:00

R1

**S19 - Symposium 19 - Ageing with cystic fibrosis****At the end of the session, the participant will be able to:**

- Predict the likely demographics of people with cystic fibrosis into the future
- Discuss the challenges of cystic fibrosis diabetes and its impact on ageing with cystic fibrosis
- Analyze the role that renal disease may have in the ageing cystic fibrosis population
- Define the risks associated with obesity in cystic fibrosis and identify challenges associated with cardiovascular health

Chair: Eitan Kerem, IL

Chair: Stuart Elborn, GB

**The evolving age profile of people with cystic fibrosis - a view to the future**

10:30 - 10:52

Speaker: Ruth Keogh, GB

**Cystic fibrosis related diabetes**

10:52 - 11:14

Speaker: Bruce C. Marshall, US

**Renal disease in cystic fibrosis - an emerging problem?**

11:14 - 11:36

Speaker: William Plant, IE

**Obesity and cardiovascular health**

11:36 - 12:00

Speaker: Francesco Blasi, IT

## Symposium

10:30 - 12:00

R2

**S20 - Symposium 20 - Real world data with CFTR modulators**

Chair: Silke van Koningsbruggen-Rietschel, DE

Chair: Pierre-Régis Burgel, FR

**Polypharmacy and CFTR modulators in real life**

10:30 - 10:52

Speaker: Edwin Brokaar, NL

**Post-authorisation studies: what can we learn from them?**

10:52 - 11:14

Speaker: Lutz Naehrlich, DE

**Ensuring adherence in patients on CFTR modulators**

11:14 - 11:36

Speaker: Peter Barry, GB

**CFTR modulators and disease modification: what is the effect on life expectancy?**

11:36 - 12:00

Speaker: Pierre-Régis Burgel, FR

## Symposium

10:30 - 12:00

R3

**S21 - Symposium 21 - The “haves” and the “have nots” - Psychological sequelae of CFTR modulator therapies****At the end of the session, the participant will be able to:**

- appreciate the psychological impact of not being able to access CFTR modulator therapy. It will look at those patients who have the right genotypes but aren't able to access the treatment due to financial or political reasons and then will consider those patients who don't have the genotypes necessary to access treatment.
- appreciate patient expectations of modulator therapies vs patient experience (based on a study looking at the pre-CFTRm counselling given to patients prior to commencement of therapy and what patients wished they had known in hindsight. )
- Consider the topic of anxiety associated with CFTR modulators. How much is a side-effect and how can we separate this from anxiety relating to the changes CFTR modulators bring.
- appreciate the challenges facing patients whose life expectancy may now be extended - what this means for their life choices / prospects / body image / identity.

Chair: Marieke Verkleij, NL

Chair: Kathleen Thickett, GB

**Left out in the cold - impact of ineligibility and inaccessibility**

10:30 - 10:52

Speaker: Urszula Borawska-Kowalczyk, PL

**Why didn't you warn me? - patient perspectives of modulator therapies**

10:52 - 11:14

Speaker: Nichola MacDuff, GB

Speaker: Angela Holden, GB

**Anxiety and depression - side effects or mourning missed opportunities?**

11:14 - 11:36

Speaker: Anna M. Georgiopoulos, US

**Identity crisis? - Rethinking and reshaping your life**

11:36 - 12:00

Speaker: Jacqueliën Noordhoek, NL

## Symposium

10:30 - 12:00

R4

**S22 - Symposium 22 - Impact of biofilm in cystic fibrosis****At the end of the session, the participant will be able to:**

- Identify the principal polymicrobial interactions in biofilms in CF
- Appraise the risk of nosocomial infection in people with CF due to biofilm
- Synthesize knowledge on approaches to solving biofilm issues
- Understand the impact of biofilm-associated pathogens on the immune response

Chair: Jennifer Bomberger, US

Chair: Tom Coenye, BE

**Interactions between viruses and bacterial biofilms in the respiratory tract**

10:30 - 10:52

Speaker: Catherine Armbruster, US

**Immune responses to *Pseudomonas aeruginosa* biofilm Infections**

10:52 - 11:14

Speaker: Claus Moser, DK

**Biofilms in the hospital environment as a risk factor for patient with cystic fibrosis**

11:14 - 11:36

Speaker: Jane E. Gross, US

**Innovative approaches to treat biofilm-related infections in**

11:36 - 12:00

**CF patients***Speaker:* Tom Coenye, BE*Symposium*

10:30 - 12:00

R5

**S23 - Symposium 23 - The changing face of newborn screening for cystic fibrosis****At the end of the session, the participant will be able to:**

- Discuss current and future challenges to optimizing CF newborn screening programmes
- Understand the challenge of extended newborn screening panels and optimization of their performance for local populations
- Be aware of the issues involved when considering extending genetic screening panels

*Chair:* Jeannette Dankert-Roelse, NL*Chair:* Dario Prais, IL**Towards optimization of the newborn screening algorithm in the Netherlands**

10:30 - 10:52

*Speaker:* Karin M. de Winter - de Groot, NL**Extended variant panels in newborn screening programmes: is it still an option?**

10:52 - 11:14

*Speaker:* Denise Kay, US**Screening around the globe: feasibility and challenges in LMICs**

11:14 - 11:36

*Speaker:* Marco Zampoli, ZA*Symposium*

10:30 - 12:00

R6

**S24 - Symposium 24 - Advances in gene and cell therapies for cystic fibrosis****At the end of the session, the participant will be able to:**

- Summarise the state-of-the-art of gene therapy for cystic fibrosis
- Review the therapeutic potential of different CFTR gene editing strategies
- Assess understanding of airway epithelial cell populations for the development of stem cell therapies for CF

*Chair:* Anna Cereseto, IT*Chair:* Marianne S. Carlon, BE**Pan CFTR mutation correction using CRISPR/Cas9**

10:30 - 10:52

*Speaker:* Matthew Porteus, US**CRISPR genome editing to repair CFTR splicing mutations**

10:52 - 11:14

*Speaker:* Giulia Maule, IT**Antisense oligonucleotide-based drugs to correct premature stop codon and splice variants in cystic fibrosis**

11:14 - 11:36

*Speaker:* Yifat Oren, IL**Genetically engineered induced pluripotent stem cells (iPSCs) as disease models to test cystic fibrosis therapies**

11:36 - 12:00

*Speaker:* Ulrich Martin, DE*Satellite Symposium*

12:30 - 14:00

R1

**Satellite Symposium**Please find the detailed programme of the Satellite Symposia [here](#).



*Meet the Experts*

12:45 - 13:45

**Meet the Experts - Meet the experts 6 - Management of drug interactions with CFTR modulators**

ePoster Corner C

*Expert:* Martin Hug, DE*Expert:* Nicola J. Shaw, GB*Meet the Experts*

12:45 - 13:45

**Meet the Experts - Meet the experts 4 - 3 CFTR databases (CFTR1, CFTR2 and CFTR-France), 3 complementary sources of information for the clinician**

ePoster Corner A

*Expert:* Caroline Raynal, FR*Expert:* Karen Raraigh, US*Expert:* Carlo Castellani, IT*Meet the Experts*

12:45 - 13:45

**Meet the Experts - Meet the Experts 5 - How to cope with the fast lane and the slow lane in the clinic: caring for patients who are not eligible and those who are eligible for CFTR modulators**

ePoster Corner B

*Expert:* Carsten Schwarz, DE*Expert:* Maya Kirszenbaum, FR*Meet the Experts*

12:45 - 13:45

**Meet the Experts***ECFS Tomorrow Lounge Session*

12:45 - 13:45

**Physiotherapy in the 20s***Speaker:* Gemma E Stanford, GB*Discussant:* Brenda Button, AU*ePoster Session*

14:00 - 15:00

**Poster Viewing 2**

P112	<b>Shift of the lung microbiota in patients with cystic fibrosis following antibiotic therapy selected with AtbFinder</b> <i>Abstract Presenter:</i> Maria Vecherkovskaya, RU	14:00 - 14:00
P113	<b>Microbiology assessment in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Nadia Mazzoni, IT	14:00 - 14:00
P114	<b>Airway colonisation by filamentous fungi in patients with cystic fibrosis from a tertiary care hospital in Madrid: a two-year prevalence study</b> <i>Abstract Presenter:</i> Alfonso Pascual del Riquelme, ES	14:00 - 14:00
P115	<b>Comparison of total bacterial and <i>Pseudomonas aeruginosa</i> load during PEx between infrequent and frequent</b>	14:00 - 14:00

	<b>exacerbators</b>	
	<i>Abstract Presenter:</i> Claire J Houston, GB	
P116	<b>Effects of Symkevi™ (tezacaftor/ivacaftor) on the lung and gut microbiota in cystic fibrosis</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Ryan Marsh, GB	
P117	<b>Fungal colonisation in patients with cystic fibrosis: preliminary results from a national multicentre study</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Ainhize Maruri-Aransolo, ES	
P118	<b>Airways respiratory viral infections in cystic fibrosis</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Daniela Dolce, IT	
P119	<b>CFTR modulators therapy and lung microbiota diversity in adult cystic fibrosis patients</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Olga Voronina, RU	
P120	<b>Metaproteomics profiling of the respiratory microbiota of cystic fibrosis (CF) patients infected by <i>Mycobacterium abscessus</i></b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Pauline Hardouin, FR	
P122	<b>Identification and characterisation of a Liverpool Epidemic Strain (LES) isolate of <i>Pseudomonas aeruginosa</i>, first collected in 1986 in Calgary, Canada</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Conrad Izydorczyk, CA	
P123	<b>Role of specialised proresolving lipid mediators in the interaction between <i>Aspergillus fumigatus</i> and cystic fibrosis bronchial epithelial cells</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Valerie Urbach, FR	
P124	<b>Collateral sensitivity in multidrug-resistant <i>Pseudomonas aeruginosa</i></b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Mette Kolpen, DK	
P125	<b>Genotype-phenotype correlation of triazole-resistant pulmonary aspergillosis in chronic respiratory disease patients</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Renad Aljohani, GB	
P126	<b><i>Pseudomonas aeruginosa</i> infection during long-term suppression treatment with tobramycin inhalation powder (TIP)</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Ross P. McCleave, GB	
P127	<b>Haemophilus influenza and antimicrobial resistance in children and young people with cystic fibrosis</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Christopher Edwards, GB	
P128	<b>Epidemiological significance of <i>Achromobacter spp.</i> chronic lung infection in patients with cystic fibrosis</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Marina Chernukha, RU	
P129	<b>Evidence for a role of <i>Achromobacter xylosoxidans</i> VBNC forms in chronic cystic fibrosis lung infection</b>	14:00 - 14:00
	<i>Abstract Presenter:</i> Nadia Mazzoni, IT	
P130	<b><i>Achromobacterspp.</i> phenotypic differences between chronic</b>	14:00 - 14:00

	<b>and occasional lung infection in cystic fibrosis</b> <i>Abstract Presenter:</i> Giulia Maria Saitta, IT	
P131	<b>Clinical impact of <i>Aspergillus fumigatus</i> in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Giovanna Pisi, IT	14:00 - 14:00
P132	<b>Microbiological monitoring of chronic lung infection with <i>Achromobacter spp.</i> in cystic fibrosis patients</b> <i>Abstract Presenter:</i> Lusine Avetisyan, RU	14:00 - 14:00
P133	<b>Prevalence and factors associated with isolation of <i>Aspergillus</i> from sputum in patients with cystic fibrosis (CF)</b> <i>Abstract Presenter:</i> Elena Gjinovska-Tasevska,	14:00 - 14:00
P134	<b>Prevalence of multi-drug antimicrobial-resistant bacteria in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Giovanna Pisi, IT	14:00 - 14:00
P135	<b>Comparative characteristics of patients with nontuberculous mycobacteria (NTM) in the Russian Federation according to the 2020 Registry</b> <i>Abstract Presenter:</i> Elena Kondratyeva, RU	14:00 - 14:00
P138	<b>Biochemical detection of <i>Pseudomonas aeruginosa</i> in sputum and urine from children with cystic fibrosis</b> <i>Abstract Presenter:</i> Hatice Nur Cömert, DK	14:00 - 14:00
P139	<b>Colistin-rifampicin combination is efficient against biofilms of colistin-resistant <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients</b> <i>Abstract Presenter:</i> Oana Ciofu, DK	14:00 - 14:00
P140	<b>Eradication treatment of <i>Pseudomonas aeruginosa</i> infections in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Aynur Gulieva, TR	14:00 - 14:00
P141	<b>Interaction between bacteria in the cystic fibrosis airways</b> <i>Abstract Presenter:</i> Enna E. Gibson, GB	14:00 - 14:00
P142	<b>Upper and lower airways microbiological status in cystic fibrosis patients in stable conditions and in lung transplant patients</b> <i>Abstract Presenter:</i> Daniela Dolce, IT	14:00 - 14:00
P143	<b>Bronchopulmonary infection/colonisation in Spanish cystic fibrosis patients: preliminary results of a multicentre study</b> <i>Abstract Presenter:</i> Ainhize Maruri-Aransolo, ES	14:00 - 14:00
P144	<b>Impact of the sex steroid hormone estradiol on biofilm formation and phenotype of <i>Pseudomonas aeruginosa</i> isolates from cystic fibrosis patients</b> <i>Abstract Presenter:</i> Jiwar Al-Zawity, DE	14:00 - 14:00
P145	<b>Monitoring of pulmonary infections in the danish cystic fibrosis cohort during CFTR modulator therapy implementation</b> <i>Abstract Presenter:</i> Majbritt Jeppesen, DK	14:00 - 14:00
P146	<b>Microbiological diagnostic procedures for respiratory cystic</b>	14:00 - 14:00

	<b>fibrosis samples: results of a survey in Italian laboratories</b> <i>Abstract Presenter:</i> Daniela Dolce, IT	
P147	<b><i>In vitro</i> sensitivity of Gram-negative cystic fibrosis isolates to a 4<sup>th</sup> generation fluoroquinolone</b> <i>Abstract Presenter:</i> Patrick Farrell, GB	14:00 - 14:00
P148	<b>Parental perspectives with sending respiratory tract specimens for microbiology from home in children with cystic fibrosis - experience from a tertiary service provider in the Northwest United Kingdom</b> <i>Abstract Presenter:</i> Anirban Maitra, GB	14:00 - 14:00
P149	<b>The association between the cumulative dose of aminoglycoside exposure and hearing loss in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Cansu Yilmaz Yegit, TR	14:00 - 14:00
P150	<b>Antimicrobial prescribing in people with cystic fibrosis: exploring inhaled antibiotic use for <i>Pseudomonas aeruginosa</i> infections across the ECFS-CTN</b> <i>Abstract Presenter:</i> Callum Matthew Sloan, GB	14:00 - 14:00
P151	<b>Drug sensitivity of <i>Mycobacterium abscessus</i> in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Elena Kondratyeva, RU	14:00 - 14:00
P152	<b>Trends in intravenous antibiotic prescriptions pre- and post-introduction of Kaftrio in a large UK adult cystic fibrosis centre</b> <i>Abstract Presenter:</i> Jocelyn Choyce, GB	14:00 - 14:00
P153	<b>Hypersensitivity reactions to antibiotics in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Aleksandra Kowalik, SE	14:00 - 14:00
P154	<b>Cough swabs are not a suitable alternative to a sputum culture for fungal culture to isolate <i>Aspergillus fumigatus</i>.</b> <i>Abstract Presenter:</i> Natalie Francis, GB	14:00 - 14:00
P155	<b>Paws for thought: sniffer dogs for infection surveillance in non-sputum-producing people with cystic fibrosis</b> <i>Abstract Presenter:</i> John King, GB	14:00 - 14:00
P156	<b>Patterns of liver dysfunction and the development of a pathway for liver monitoring in adults with cystic fibrosis (CF) on elexacaftor/tezacaftor/ivacaftor (ETI): a quality improvement project</b> <i>Abstract Presenter:</i> James Sun, GB	14:00 - 14:00
P157	<b>A modified rapid review of gastrointestinal symptoms in people with cystic fibrosis on cystic fibrosis transmembrane regulator modulator therapies</b> <i>Abstract Presenter:</i> Darren Sills, GB	14:00 - 14:00
P158	<b>What is the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on clinical response of cystic fibrosis patients aged <math>\geq 40</math> years and their co-morbidities?</b> <i>Abstract Presenter:</i> Karuna Sapru, GB	14:00 - 14:00

P159	<b>Modifications of anthropometric parameters and body composition after Kaftrio in a group of adolescents and young adults</b> <i>Abstract Presenter:</i> Silvia Rigon, IT	14:00 - 14:00
P160	<b>"Seeing a trend" - increasing vitamin A levels on elexacaftor/tezacaftor/ivacaftor therapy</b> <i>Abstract Presenter:</i> David Proud, GB	14:00 - 14:00
P161	<b>Body mass index change in adult patients with cystic fibrosis following the introduction of triple CFTR therapy ivacaftor/tezacaftor/elexacaftor: a regional adult cystic fibrosis centre experience</b> <i>Abstract Presenter:</i> Neil Patel, GB	14:00 - 14:00
P162	<b>Body composition assessment in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Veronica Zamponi, IT	14:00 - 14:00
P163	<b>Single-centre experience of changes in nutritional parameters in the first 12 months of elexacaftor/tezacaftor/ivacaftor (ETI / Kaftrio) treatment</b> <i>Abstract Presenter:</i> Joanna Snowball, GB	14:00 - 14:00
P164	<b>Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis: cross-sectional analysis and effect of elexacaftor/tezacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Michela Francalanci, IT	14:00 - 14:00
P165	<b>Exploring weight change and subjective experiences on Kaftrio in adults with cystic fibrosis</b> <i>Abstract Presenter:</i> Lidia Sheibani, GB	14:00 - 14:00
P166	<b>"The party is over because I now have a sensible diet" - the experience of people with cystic fibrosis on CFTR modulators</b> <i>Abstract Presenter:</i> Sarah Collins, GB	14:00 - 14:00
P167	<b>Pancreatic enzyme replacement therapy intake and gastrointestinal symptoms in adults with cystic fibrosis: a cross-sectional study in Copenhagen, Denmark</b> <i>Abstract Presenter:</i> Mette Frahm Olsen, DK	14:00 - 14:00
P168	<b>Gastrointestinal (GI) symptoms and their impact on quality of life in cystic fibrosis (CF) patients</b> <i>Abstract Presenter:</i> Ivana Arnaudova Danevska,	14:00 - 14:00
P169	<b>Psychometric properties of the gastrointestinal symptom tracker self-report measure</b> <i>Abstract Presenter:</i> Sonia Graziano, IT	14:00 - 14:00
P170	<b>An assessment of terminal ileum morphology, using magnetic resonance imaging, in people with cystic fibrosis</b> <i>Abstract Presenter:</i> Grace Lim, GB	14:00 - 14:00
P171	<b>Improved diagnosis and treatment of distal intestinal obstruction syndrome (DIOS) with a simplified treatment routine</b> <i>Abstract Presenter:</i> Marita Gilljam, SE	14:00 - 14:00

P172	<b>Screening for constipation in cystic fibrosis (CF): what are we missing?</b> <i>Abstract Presenter:</i> Jennifer Still, GB	14:00 - 14:00
P173	<b>Increased prevalence of celiac disease in patients with cystic fibrosis: a systematic review and meta analysis</b> <i>Abstract Presenter:</i> Marcell Imrei, HU	14:00 - 14:00
P174	<b>Effects of proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: a matched cohort study</b> <i>Abstract Presenter:</i> CALOGERO SATHYA SCIARRABBA, IT	14:00 - 14:00
P175	<b>How accurate is the glucose management indicator calculated by continuous glucose monitoring compared to the blood HbA1c reading in patients with cystic fibrosis?</b> <i>Abstract Presenter:</i> Dion-Emily Manning, GB	14:00 - 14:00
P177	<b>Adults with Cystic Fibrosis-Related Diabetes have a significantly elevated rate of gastrointestinal symptoms assessed with the CFAbd-Score</b> <i>Abstract Presenter:</i> Laura Caley, GB	14:00 - 14:00
P178	<b>A feasibility assessment of delivering a glycaemic index dietary intervention for managing glucose abnormalities in people with cystic fibrosis</b> <i>Abstract Presenter:</i> Laura Birch, GB	14:00 - 14:00
P179	<b>Glycaemic index dietary intervention in cystic fibrosis: preliminary findings from a feasibility study of dietary manipulation</b> <i>Abstract Presenter:</i> Laura Birch, GB	14:00 - 14:00
P180	<b>Clinical practice versus guidelines for the screening of Cystic Fibrosis-Related Diabetes (CFRD): a French survey of 47 centres</b> <i>Abstract Presenter:</i> Laurence Weiss, FR	14:00 - 14:00
P181	<b>The effects of linagliptin in patients with a diagnosis of Cystic Fibrosis-Related Diabetes</b> <i>Abstract Presenter:</i> Josie Cunningham, GB	14:00 - 14:00
P182	<b>Adiponectin, glucose metabolism and body composition in cystic fibrosis</b> <i>Abstract Presenter:</i> Bibi Uhre Nielsen, DK	14:00 - 14:00
P183	<b>Informative value of fructosamine in diagnosis of carbohydrate metabolism disorders in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Nadezhda Lyabina, RU	14:00 - 14:00
P184	<b>An evaluation of virtual Cystic Fibrosis-Related Diabetes (CFRD) clinics in the adult service during the covid-19 pandemic in Northern Ireland (NI)</b> <i>Abstract Presenter:</i> Emma Molloy, GB	14:00 - 14:00
P186	<b>High vitamin A in children under 5 years of age</b> <i>Abstract Presenter:</i> Órla Cahill, GB	14:00 - 14:00
P187	<b>Nutritional status and its relation with lung function and</b>	14:00 - 14:00

	<b>vitamin D3 level in cystic fibrosis patients</b> <i>Abstract Presenter:</i> Ivana Arnaudova Danevska,	
P188	<b>Vitamin D status at Bristol Adult CF Centre (BACFC) during the COVID-19 pandemic and following the introduction of the multivitamin Paravit CF</b> <i>Abstract Presenter:</i> Anna Keele, GB	14:00 - 14:00
P189	<b>Assessment of total dietary salt intake: highlighting the need for regular detailed dietetic analysis of total salt intake in Liverpool, UK paediatric cystic fibrosis centre</b> <i>Abstract Presenter:</i> Claire A. Berry, GB	14:00 - 14:00
P190	<b>Features of dosing of enzyme replacement therapy in children with cystic fibrosis in the Russian Federation: cross-sectional study</b> <i>Abstract Presenter:</i> Tatyana Maksimychева, RU	14:00 - 14:00
P191	<b>Self-compassion explains the positive relationship of mindful eating to uncontrolled and emotional eating in adults with cystic fibrosis</b> <i>Abstract Presenter:</i> Michail Mantzios, GB	14:00 - 14:00
P192	<b>Early adrenal activation in boys with cystic fibrosis may explain impaired final height</b> <i>Abstract Presenter:</i> Gizem Tamer, NL	14:00 - 14:00
P193	<b>Thermal sensation and clinical characteristics of patients with cystic fibrosis during extreme heat conditions</b> <i>Abstract Presenter:</i> Pinelopi Anagnostopoulou, CH	14:00 - 14:00
P194	<b>Evaluation of bone mineral density indicators in children with cystic fibrosis: dynamics of indicators over 15 years</b> <i>Abstract Presenter:</i> Elena Zhekaite, RU	14:00 - 14:00
P196	<b>Detecting bone disease in patients with cystic fibrosis: influence of genetic and clinical factors over reduced bone mass</b> <i>Abstract Presenter:</i> Tatjana Jakovska Maretti,	14:00 - 14:00
P197	<b>Bone health status over time in people with cystic fibrosis and adherence to assessment of bone health guidelines at University Hospital Limerick</b> <i>Abstract Presenter:</i> Audrey Tierney, IE	14:00 - 14:00
P198	<b>Bone health monitoring and treatment at an adult cystic fibrosis centre</b> <i>Abstract Presenter:</i> Darren Sills, GB	14:00 - 14:00
P199	<b>Bone health and associated factors at an adult cystic fibrosis unit</b> <i>Abstract Presenter:</i> Darren Sills, GB	14:00 - 14:00
P200	<b>The prevalence of laryngopharyngeal reflux and sino-nasal symptoms in adults with cystic fibrosis</b> <i>Abstract Presenter:</i> Stephen Bourke, GB	14:00 - 14:00
P201	<b>Bowel screening for cancer in pre-transplant people with cystic fibrosis and the accuracy of faecal immunochemical testing</b>	14:00 - 14:00

	<i>Abstract Presenter:</i> Aoife Lillis, GB	
P202	<b>CFTR modulation may help refine transplant decisions in lung-liver transplant candidates</b> <i>Abstract Presenter:</i> Christiane Knoop, BE	14:00 - 14:00
P203	<b>Cystic fibrosis-related diseases at the Centre for Cystic Fibrosis, Institute for Respiratory Diseases in Children in Skopje, Republic of North Macedonia</b> <i>Abstract Presenter:</i> Sonja Momchilovikj,	14:00 - 14:00
P204	<b>Elexacaftor/tezacaftor/ivacaftor - positive effects on quality of life using the AWEScore and exercise capacity using the A-STEP in adults with end stage cystic fibrosis</b> <i>Abstract Presenter:</i> Brenda Button, AU	14:00 - 14:00
P205	<b>Kaftrio improves VO<sub>2max</sub> in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Thomas Kent, GB	14:00 - 14:00
P207	<b>Spirometric values and six-minute walking distance in cystic fibrosis patients on elexacaftor/texacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Arianna Peruzzi, IT	14:00 - 14:00
P208	<b>A retrospective observational study of the effects of Kaftrio on the current cohort of patients at Nottingham University Hospitals NUH trust</b> <i>Abstract Presenter:</i> Kate Hardiman, GB	14:00 - 14:00
P209	<b>Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?</b> <i>Abstract Presenter:</i> Stefanie Dillenhöfer, DE	14:00 - 14:00
P210	<b>Association of anaerobic threshold variables from cardiopulmonary exercise testing with the risk for exacerbation in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Natália Evangelista Campos, BR	14:00 - 14:00
P211	<b>Ventilatory parameters during incremental exercise in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Virginia D Alessandro, AR	14:00 - 14:00
P212	<b>The impact of cystic fibrosis-related diabetes on exercise capacity</b> <i>Abstract Presenter:</i> Richard Porter, GB	14:00 - 14:00
P213	<b>The three-minute step test as a predictor of exacerbations in children and adolescents with cystic fibrosis</b> <i>Abstract Presenter:</i> Márcio Vinícius Fagundes Donadio, BR	14:00 - 14:00
P214	<b>A comparison of airway clearance devices in adult cystic fibrosis patients: NIPPY Clearway2 versus Intermittent Positive Pressure Breathing (IPPB)</b> <i>Abstract Presenter:</i> Verity Yarwood, GB	14:00 - 14:00
P215	<b>Airway clearance physiotherapy and health-related quality of life in cystic fibrosis - a substudy of a series of n-of-1 randomised controlled trials</b> <i>Abstract Presenter:</i> Sandra Gursli, NO	14:00 - 14:00
P216	<b>The short-term influence of chest physiotherapy on lung</b>	14:00 - 14:00



	<b>function parameters in children with cystic fibrosis and primary ciliary dyskinesia</b> <i>Abstract Presenter:</i> Mieke Boon, BE	
P217	<b>Exercise as airway clearance therapy (ExACT) in cystic fibrosis: a UK-based e-Delphi survey of patients, caregivers and health professionals</b> <i>Abstract Presenter:</i> Zoe Saynor, GB	14:00 - 14:00
P218	<b>Calibration and cross-validation of accelerometry in children and adolescents with cystic fibrosis</b> <i>Abstract Presenter:</i> Mayara S. Bianchim, GB	14:00 - 14:00
P219	<b>Establishing a review process for patients using non-invasive ventilation for airway clearance in the St. Bartholomew's cystic fibrosis adult population</b> <i>Abstract Presenter:</i> Georgie Goodwin, GB	14:00 - 14:00
P220	<b>Assessment of use of Manchester musculoskeletal screening tool in cystic fibrosis adults</b> <i>Abstract Presenter:</i> Nicola Hodgson, GB	14:00 - 14:00
P221	<b>Tension-free vaginal tape - a 15-year review of effect on urinary incontinence in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Verity Yarwood, GB	14:00 - 14:00
P222	<b>To assess measured frailty compared to multidisciplinary perception of frailty in the adult cystic fibrosis population</b> <i>Abstract Presenter:</i> Paul Wilson, GB	14:00 - 14:00
P223	<b>Bare Bones - a re-audit of bone health management in patients with cystic fibrosis at St. Vincent's University Hospital</b> <i>Abstract Presenter:</i> Sarah Kelly, IE	14:00 - 14:00
P224	<b>Evolution of dry powder inhaled colistimethate sodium (Colobreathe) in a large adult cystic fibrosis centre</b> <i>Abstract Presenter:</i> Verity Yarwood, GB	14:00 - 14:00
P225	<b>Long-term tolerability and use of tobipodhaler in people with cystic fibrosis</b> <i>Abstract Presenter:</i> Zelda Beverley, GB	14:00 - 14:00
P226	<b>Our evolving prescribing practice: inhaled medication prescription changes over five years at the West Midlands Adult Cystic Fibrosis Centre</b> <i>Abstract Presenter:</i> Catherine Brown, GB	14:00 - 14:00
P227	<b>"CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis</b> <i>Abstract Presenter:</i> Martin Jirásek, CZ	14:00 - 14:00
P228	<b>Using CFHealthHub nebuliser duration data to support continuous improvement by optimising inhaled therapy duration to reduce treatment burden within a digital learning health system</b> <i>Abstract Presenter:</i> Robert D Sandler, GB	14:00 - 14:00
P229	<b>The introduction of an adherence support clinic in a large UK adult cystic fibrosis centre</b>	14:00 - 14:00

	<i>Abstract Presenter:</i> Jocelyn Choyce, GB	
P230	<b>Time matters: burden of respiratory physiotherapy in adolescents with cystic fibrosis (CF) and their caregivers</b> <i>Abstract Presenter:</i> Chiara Blardone, IT	14:00 - 14:00
P231	<b>Steps Ahead: optimising physical activity in adults with cystic fibrosis - a pilot randomised trial using wearable technology, goal setting and text message feedback</b> <i>Abstract Presenter:</i> Audrey Tierney, IE	14:00 - 14:00
P232	<b>Feasibility and added value of the computer game "Sparky©" when learning spirometry in preschool children with cystic fibrosis</b> <i>Abstract Presenter:</i> Myriam Vreys, BE	14:00 - 14:00
P233	<b>Adherence of nebuliser use in children with cystic fibrosis</b> <i>Abstract Presenter:</i> Kieren James Lock, GB	14:00 - 14:00
P234	<b>CoachMois: the experience of an adapted physical activity challenge online at the Roscoff Cystic Fibrosis Centre (Brittany, FR)</b> <i>Abstract Presenter:</i> Aline DUBOIS, FR	14:00 - 14:00
P235	<b>What influence can educational videos have on daily physical therapy in children, adolescents and young adults with cystic fibrosis? A pilot study</b> <i>Abstract Presenter:</i> Kevin Cobb, AT	14:00 - 14:00
P236	<b>Commit to Fit - access to gym space for young people with cystic fibrosis in partnership with Helping Hand charity</b> <i>Abstract Presenter:</i> Niju Baby, GB	14:00 - 14:00
P237	<b>Exercise immunology and cystic fibrosis</b> <i>Abstract Presenter:</i> GAUCHEZ Hugues, FR	14:00 - 14:00
P238	<b>Family participation in cystic fibrosis care</b> <i>Abstract Presenter:</i> Janne Houben, BE	14:00 - 14:00
P239	<b>The experience of virtual visits and home spirometry in caregivers of children with cystic fibrosis</b> <i>Abstract Presenter:</i> Viktoria Mellqvist, SE	14:00 - 14:00
P240	<b>Elexacaftor/tezacaftor/ivacaftor treatment improves cystic fibrosis quality of life over multiple domains</b> <i>Abstract Presenter:</i> Nicola Jane Robinson, GB	14:00 - 14:00
P241	<b>One month with elexacaftor/tezacaftor/ivacaftor in an Italian sample: quality of life and mental health</b> <i>Abstract Presenter:</i> Sonia Graziano, IT	14:00 - 14:00
P242	<b>Young people's views on Kaftrio: a peer research project</b> <i>Abstract Presenter:</i> Eleanor Lee Mindel, GB	14:00 - 14:00
P243	<b>Psychosocial impact of six months of treatment with Symkevi among adult cystic fibrosis patients</b> <i>Abstract Presenter:</i> Sue Braun, BE	14:00 - 14:00
P244	<b>The experiences of taking Kaftrio for cystic fibrosis</b> <i>Abstract Presenter:</i> Cicely Mathews, GB	14:00 - 14:00

P245	<b>Kaftrio Impact and Side-effect Survey (KISS)</b> <i>Abstract Presenter:</i> Angela Holden, GB	14:00 - 14:00
P246	<b>Improving assessment of palliative care needs among cystic fibrosis children: A Delphi study of the ADAPT-Cystic Fibrosis communication guide</b> <i>Abstract Presenter:</i> Anna M. Georgiopoulos, US	14:00 - 14:00
P247	<b>Dutch translation of the gastrointestinal (GI) symptom tracker for people with cystic fibrosis</b> <i>Abstract Presenter:</i> Marieke Verkleij, NL	14:00 - 14:00
P248	<b>Parental reports of the oral health-related quality of life and associated factors in children with cystic fibrosis (CF)</b> <i>Abstract Presenter:</i> Hande Ilgin Sisman, TR	14:00 - 14:00
P249	<b>Awareness of the potential benefits of occupational therapy in a cystic fibrosis multi-disciplinary team</b> <i>Abstract Presenter:</i> Wendy Foo, GB	14:00 - 14:00
P250	<b>Development of a new information resource on fasting during Ramadan and cystic fibrosis</b> <i>Abstract Presenter:</i> J Carter, GB	14:00 - 14:00
P251	<b>The effect of breathing exercise on the quality of life of 3-12 year-old patients with cystic fibrosis and their families</b> <i>Abstract Presenter:</i> mine kalyoncu, TR	14:00 - 14:00
P252	<b>A service improvement project: identifying and addressing problems experienced by adults with cystic fibrosis relating to the supply of medicines in primary care</b> <i>Abstract Presenter:</i> Monika Chawla, GB	14:00 - 14:00
P253	<b>Using quality improvement to develop transition to adult care at a UK cystic fibrosis centre</b> <i>Abstract Presenter:</i> Louise Warnock, GB	14:00 - 14:00
P254	<b>Transition to adult care in children with cystic fibrosis - experience over a decade from a large tertiary centre in the northwest United Kingdom</b> <i>Abstract Presenter:</i> Anirban Maitra, GB	14:00 - 14:00
P255	<b>Transitioning to adult services for children with cystic fibrosis: what matters to all stakeholders?</b> <i>Abstract Presenter:</i> Verena Michael, GB	14:00 - 14:00
P256	<b>Change in the anxiety levels of children with cystic fibrosis and their mothers at the beginning of the COVID-19 pandemic and after one year</b> <i>Abstract Presenter:</i> Tugba Sismanlar Eyuboglu, TR	14:00 - 14:00
P257	<b>Who's talking about cystic fibrosis continued: the effects of the COVID-19 pandemic on the cystic fibrosis online landscape</b> <i>Abstract Presenter:</i> Hisham Ibrahim, IE	14:00 - 14:00

ePoster Session

14:00 - 15:00

ePoster Sessions

*ePoster Session*

14:00 - 15:00

**ePoster Session 6 - Modulators and other approaches: from the lab to the patient**

ePoster Corner C

*Leader:* Isabelle Sermet-Gaudelus, FR*Leader:* Guido Veit, CA

EPS6.01	<b>Characterisation of F508del-CFTR rescue by corrector PTI-801</b>	14:00 - 14:07
	<i>Abstract Presenter:</i> Miquéias Lopes-Pacheco, PT	
EPS6.02	<b>CFTR-modulators improve bicarbonate transport via the CFTR variant D1152H (c.3453G&gt;C) in primary human intestinal epithelial cells</b>	14:07 - 14:14
	<i>Abstract Presenter:</i> Dora Angyal, NL	
EPS6.03	<b>Enabling RNA-based gene modification in high-throughput screenings using cystic fibrosis patient-derived organoids</b>	14:14 - 14:21
	<i>Abstract Presenter:</i> Cinthya del Angel Zuvirie, NL	
EPS6.04	<b>Specialised pro-resolving mediators' biosynthesis by cystic fibrosis airway epithelial cells and their impact on mucociliary clearance</b>	14:21 - 14:28
	<i>Abstract Presenter:</i> Maëlle Briottet, FR	
EPS6.05	<b>ELX/TEZ/IVA vs. TEZ/IVA in intestinal organoids: analysis of 63 individuals with cystic fibrosis</b>	14:28 - 14:35
	<i>Abstract Presenter:</i> Eva Furstova, CZ	
EPS6.07	<b>SpliSense's ASO SPL84-23-1 properly distributes and is retained in cystic fibrosis-like mice lungs</b>	14:35 - 14:42
	<i>Abstract Presenter:</i> Gili Hart, IL	
EPS6.08	<b>Second-hand smoke exposure reduces the clinical efficacy of ivacaftor in G551D: results from the GOAL study</b>	14:42 - 14:49
	<i>Abstract Presenter:</i> Steven M. Rowe, US	
EPS6.09	<b>A discrete choice experiment to quantify the influence of trial features on patients' decisions to join cystic fibrosis clinical trials</b>	14:49 - 14:56
	<i>Abstract Presenter:</i> Rebecca Dobra, GB	
EPS6.10	<b>A real-world study evaluating the impact of elexacaftor/tezacaftor/ivacaftor treatment on medication adherence in cystic fibrosis</b>	14:56 - 14:56
	<i>Abstract Presenter:</i> Karen Lester, IE	

*ePoster Session*

14:00 - 15:00

**ePoster Session 4 - When CF encounters Sars-Cov2 Infection and vaccination**

ePoster Corner A

*Leader:* Daniel Peckham, GB*Leader:* Carla Colombo, IT

EPS4.01	<b>The impact of the SARS-CoV-2 pandemic on people with cystic fibrosis in Ireland: did individuals maintain their key health outcomes?</b>	14:00 - 14:06
	<i>Abstract Presenter:</i> Laura Kirwan, IE	

EPS4.02	<b>Impact of COVID-19 on the disease course in cystic fibrosis? A Registry-based study</b> <i>Abstract Presenter:</i> Josefien Vandekerckhove, BE	14:06 - 14:12
EPS4.03	<b>Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK</b> <i>Abstract Presenter:</i> Dawn Lau, GB	14:12 - 14:18
EPS4.04	<b>Evaluation of burden of the COVID-19 pandemic among the cystic fibrosis community in Brno, Czech Republic</b> <i>Abstract Presenter:</i> Miriam Mala, CZ	14:18 - 14:24
EPS4.05	<b>Evolving cystic fibrosis care during COVID-19: a single-centre experience</b> <i>Abstract Presenter:</i> Giulia Spoletini, GB	14:24 - 14:30
EPS4.06	<b>Antibody response to administration of two doses of the BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis</b> <i>Abstract Presenter:</i> Gianfranco Alicandro, IT	14:30 - 14:36
EPS4.07	<b>Covid-19 early vaccination campaign in cystic fibrosis (CF) Italian patients: the experience of the Italian Society for the Study of Cystic Fibrosis (SIFC)</b> <i>Abstract Presenter:</i> Francesca Lucca, IT	14:36 - 14:42
EPS4.08	<b>COVID-19 vaccine uptake in adult people with cystic fibrosis</b> <i>Abstract Presenter:</i> Muhammad Haris Mir, GB	14:42 - 14:48
EPS4.09	<b>COVID-19 vaccination in households of paediatric cystic fibrosis patients - experience of The Cystic Fibrosis Centre in Zagreb, Croatia</b> <i>Abstract Presenter:</i> Ivan Bambir, HR	14:48 - 14:54
EPS4.10	<b>Evaluation of possible adverse events in relationship to the SARS-CoV-2 vaccination in cystic fibrosis patients with or without lung transplantation: a retrospective single-centre case series</b> <i>Abstract Presenter:</i> Fiorenza Gautschi, CH	14:54 - 15:00

*ePoster Session*

14:00 - 15:00

**ePoster Session 5 - Complementary aspects on CF pathology and treatment**

ePoster Corner B

*Leader:* Carsten Schwarz, DE*Leader:* Lieven Dupont, BE

EPS5.01	<b>Cystic fibrosis (CF) patients chronically infected with <i>Pseudomonas aeruginosa</i> have widespread alterations in both innate and adaptive immunity</b> <i>Abstract Presenter:</i> Mads Lausen, DK	14:00 - 14:06
EPS5.02	<b>Effect of omalizumab on glucocorticoid use and lung function in the treatment of allergic bronchopulmonary aspergillosis in people with cystic fibrosis: a systematic review and meta-analysis</b> <i>Abstract Presenter:</i> J. Stuart Elborn, GB	14:06 - 14:12
EPS5.03	<b>Down-regulation of <i>Aspergillus fumigatus</i>-induced IFN<math>\beta</math> and</b>	14:12 - 14:18

	<b>IFN<math>\gamma</math>1 expression in cystic fibrosis bronchial epithelial cells is partially rescued by CFTR modulator treatment</b>	
	<i>Abstract Presenter:</i> Sarah Lavery, GB	
EPS5.04	<b>Chronic exposure to <i>Aspergillus fumigatus</i> leads to cell death and increased eosinophilia in the airways of cystic fibrosis mice</b>	14:18 - 14:25
	<i>Abstract Presenter:</i> Thomas J Williams, GB	
EPS5.05	<b>Cystic fibrosis chronic rhinosinusitis: implications of automated versus manual sinus CT analysis and patient-reported symptoms</b>	14:25 - 14:32
	<i>Abstract Presenter:</i> Jennifer Taylor-Cousar, US	
EPS5.06	<b>Implementing tablet-based ototoxicity screening in adults with cystic fibrosis</b>	14:32 - 14:39
	<i>Abstract Presenter:</i> Shereen Boreland, GB	
EPS5.07	<b>Alkalosis-induced hypoventilation in cystic fibrosis: the importance of efficient renal adaptation</b>	14:39 - 14:46
	<i>Abstract Presenter:</i> Peder Berg, DK	
EPS5.08	<b>The effects on systemic inflammation of elxacaftor/tezacaftor/ivacaftor</b>	14:46 - 14:53
	<i>Abstract Presenter:</i> Nicola Robinson, GB	
EPS5.09	<b>Comparison of the Lung Clearance Index in preschool children with primary ciliary dyskinesia and cystic fibrosis</b>	14:53 - 15:00
	<i>Abstract Presenter:</i> Jobst Röhm, DE	
<i>ECFS Tomorrow Lounge Session</i>		
14:15 - 15:15		
<b>Challenging conversations in healthcare: transforming preparedness through simulation</b>		
<i>Chair:</i> Gerry Gormley, GB		
<i>Workshop</i>		
15:00 - 16:30		
R1		
<b>WS12 - WS12: Insight into the pathophysiology of CF pulmonary disease</b>		
<i>Chair:</i> Hettie Janssens, NL		
<i>Chair:</i> Isabelle Fajac, FR		
WS12.01	<b>Acute pulmonary exacerbations in early cystic fibrosis lung disease are associated with CD3 and PD-1 modulation on lung T cells</b>	15:00 - 15:15
	<i>Abstract Presenter:</i> Vincent Giacalone, US	
WS12.02	<b>BAFF and other soluble factors in airway samples are linked with pathological cystic fibrosis neutrophil phenotype in early childhood</b>	15:15 - 15:30
	<i>Abstract Presenter:</i> Craig J. Schofield, AU	
WS12.03	<b>PD-1 expression on airway macrophages in early cystic fibrosis lung disease coincides with decreased expression of phagocytosis-related markers</b>	15:30 - 15:45
	<i>Abstract Presenter:</i> Lisa Slimmen, NL	
WS12.04	<b>Understanding the mechanism of <i>S. aureus</i> killing by neutrophils in the cystic fibrosis airway environment</b>	15:45 - 16:00

*Abstract Presenter:* Kayla Fantone, US

- WS12.05      **CFTR-TGFβ<sub>1</sub> interaction in inflammatory processes in healthy and CFTR-mutated human bronchial epithelial cells**      16:00 - 16:15  
*Abstract Presenter:* Jan Christoph Thomassen, DE

- WS12.06      **Hypertonic saline triggers inflammatory responses in human macrophages**      16:15 - 16:30  
*Abstract Presenter:* Francesca Sposito, GB

### Workshop

15:00 - 16:30

R2

### **WS13 - WS13: Characterisation of the airway microbiota in cystic fibrosis**

*Chair:* Tavs Qvist, DK

*Chair:* Pavel Drevinec, CZ

- WS13.01      **An invisible threat? *Aspergillus*-positive cultures and co-infecting bacteria in airway samples**      15:00 - 15:15  
*Abstract Presenter:* Dominic Hughes, GB

- WS13.02      **Studying the proteome of respiratory samples from cystic fibrosis patients by shotgun proteomics: differences between exacerbation and clinical stability phases**      15:15 - 15:30  
*Abstract Presenter:* Juan de Dios Caballero, ES

- WS13.03      **Real-world relevancy of qPCR for early detection of *Pseudomonas aeruginosa* infection in people with cystic fibrosis (pwCF)**      15:30 - 15:45  
*Abstract Presenter:* Geneviève Héry-Arnaud, FR

- WS13.04      ***In vivo* lung inflammation induced by *Achromobacter* spp. clinical isolates with different virulence characteristics**      15:45 - 16:00  
*Abstract Presenter:* Angela Sandri, IT

- WS13.05      **Mapping and tackling diversity in antibiotic resistance of sputum isolates in cystic fibrosis**      16:00 - 16:15  
*Abstract Presenter:* Sara Van den Bossche, BE

- WS13.06      **Development of antibiotic resistance reveals diverse evolutionary pathways to face the complex and dynamic environment of a long-term treated patient**      16:15 - 16:30  
*Abstract Presenter:* Claudia A Colque, DK

### Workshop

15:00 - 16:30

R3

### **WS14 - WS14: Measuring outcomes: where physiotherapy makes a difference**

*Chair:* Emma Raywood, GB

*Chair:* Wolfgang Gruber, DE

- WS14.01      **Outcome measures for airway clearance - better the devil you know? Perspectives from adults with cystic fibrosis (CF)**      15:00 - 15:15  
*Abstract Presenter:* Gemma E Stanford, GB

- WS14.02      **Time to first pulmonary exacerbation (PE) in children and adolescents with cystic fibrosis (CF): insights from spirometry, Lung Clearance Index (LCI) and symptoms-limited exercise test (SLET)**      15:15 - 15:30  
*Abstract Presenter:* Alessandra Mariani, IT

WS14.03	<b>Cystic Fibrosis-Related Diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis: a cross-sectional analysis of an international multicentre trial (ACTIVATE-CF)</b> <i>Abstract Presenter:</i> Thomas Radtke, CH	15:30 - 15:45
WS14.04	<b>The heart of the matter: is cardiac output a limiting factor for maximal exercise capacity in people with cystic fibrosis?</b> <i>Abstract Presenter:</i> Marcella Burghard, NL	15:45 - 16:00
WS14.05	<b>Normal fitness data in cystic fibrosis - a scoping review</b> <i>Abstract Presenter:</i> Owen William Tomlinson, GB	16:00 - 16:15
WS14.06	<b>A retrospective, longitudinal analysis of pulmonary function and peak oxygen uptake in children and adults with cystic fibrosis</b> <i>Abstract Presenter:</i> Hannah Morgan, GB	16:15 - 16:30
<i>Workshop</i> 15:00 - 16:30		R4
<b>WS15 - WS15: Nutrition status with and without CFTR modulators</b>		
<i>Chair:</i> Monika Mielus, PL <i>Chair:</i> Sarah Collins, GB		
WS15.01	<b>Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis of 3,100 patients</b> <i>Abstract Presenter:</i> Rita Nagy, HU	15:00 - 15:15
WS15.02	<b>A joint model for lung function and nutritional status decline with recurrent pulmonary exacerbations, death, and lung transplantation using cystic fibrosis patient Registry data</b> <i>Abstract Presenter:</i> Pedro Miranda Afonso, NL	15:15 - 15:30
WS15.03	<b>A mixed-method systematic review of body image in adults with cystic fibrosis (CF)</b> <i>Abstract Presenter:</i> Darren Sills, GB	15:30 - 15:45
WS15.04	<b>Unanticipated increase in commonly consumed dietary fat when consumed with a new lysophosphatidylcholine-rich nutritional therapy</b> <i>Abstract Presenter:</i> Virginia Stallings, US	15:45 - 16:00
WS15.05	<b>Impact of refining the U Na/Creat cut-off according to age on the diagnosis of salt depletion in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Olivia Bauraind, BE	16:00 - 16:15
WS15.06	<b>Fat-soluble vitamin status in F508del homozygous children with cystic fibrosis following commencement of lumacaftor/ivacaftor</b> <i>Abstract Presenter:</i> Aislinn Kinsella, GB	16:15 - 16:30



## Symposium

15:00 - 16:30

R5

**SS02 - SS02: Diagnosing in the liquid world of CFTR related disorders****At the end of the session, the participant will be able to:**

- appreciate the challenges inherent in the diagnostic process of CFTR related disorders
- use biomarkers of CFTR dysfunction to recognize CFTR related disorders
- perform an initial clinical evaluation of a person with a CFTR related disorder
- consider benefits and drawbacks of dedicated follow-up programmes for CFTR related disorders

Chair: Kris De Boeck, BE

Chair: Carlo Castellani, IT

**The CFTR related disorders project: introductory recommendations and work plan** 15:00 - 15:22

Speaker: Carlo Castellani, IT

**Biomarkers of CFTR dysfunction in the diagnosis of CFTR related disorders** 15:22 - 15:44

Speaker: Isabelle Sermet-Gaudelus, FR

**CFTR related disorders: the initial clinical assessment** 15:44 - 16:06

Speaker: Elke de Wachter, BE

**The CFTR related disorder clinic: advantages and challenges** 16:06 - 16:30

Speaker: Nicholas Simmonds, GB

## Workshop

15:00 - 16:30

R6

**WS16 - WS16: Beyond CFTR modulators - gene-based and alternative strategies to correct the basic defect**

Chair: Jeffrey Beekman, NL

Chair: Marianne S. Carlon, BE

WS16.01 **Correction of the drug-refractory CFTR mutation L227R by prime editing** 15:00 - 15:15

Abstract Presenter: Mattijs Bulcaen, BE

WS16.02 **Base editing strategy to repair the CFTR 2789+5G>A splicing mutation** 15:15 - 15:30

Abstract Presenter: Simone Amistadi, IT

WS16.03 **LUNAR®-CF: an mRNA replacement approach for cystic fibrosis lung disease** 15:30 - 15:45

Abstract Presenter: David Geller, GB

WS16.04 **Inhalation of SP-101 mediates hCFTRΔR transgene expression in the airways of cystic fibrosis and non-cystic fibrosis ferrets** 15:45 - 16:00

Abstract Presenter: Katherine Excoffon, US

WS16.05 **Identification of drugs activating CFTR-independent fluid secretion in nasal organoids based on a high-content screening assay** 16:00 - 16:15

Abstract Presenter: Gimano Amatngalim, NL

WS16.06 **Development of a high throughput functional screen allows drug repurposing and reveals novel drug candidates for rescuing CFTR function in patient-derived organoids with nonsense mutations** 16:15 - 16:30

*Abstract Presenter:* Sacha Spelier, NL

*ECFS Tomorrow Lounge Session*

15:15 - 16:15

**What psychosocial outcome measures are being used/ found useful in CF?**

*Chair:* Sejal Patel, GB

*Chair:* Urszula Borawska-Kowalczyk, PL

*Workshop*

17:00 - 18:30

R1

**WS17 - WS17: Clinical and biological updates on CFTR modulators**

*Chair:* Barry Plant, IE

*Chair:* David Sheppard, GB

- |         |  |               |
|---------|--|---------------|
| WS17.01 | <b>Therapeutic drug monitoring of elexacaftor, tezacaftor and ivacaftor in adult patients with cystic fibrosis</b><br><i>Abstract Presenter:</i> Susanne Naehrig, DE   | 17:00 - 17:15 |
| WS17.02 | <b>Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged two through five years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): a phase 2, open-label extension study</b><br><i>Abstract Presenter:</i> Mirjam Stahl, DE | 17:15 - 17:30 |
| WS17.03 | <b>Initiating ivacaftor (IVA) at younger vs older ages improves pulmonary outcomes in people with cystic fibrosis (pwCF): a long-term real-world study</b><br><i>Abstract Presenter:</i> Christian Merlo, US   | 17:30 - 17:45 |
| WS17.04 | <b>CFTR modulation alters the visco-elastic properties of airway mucus in cystic fibrosis patients</b><br><i>Abstract Presenter:</i> Iris Janssens, BE   | 17:45 - 18:00 |
| WS17.05 | <b>Elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis impacts airway progenitor cell function</b><br><i>Abstract Presenter:</i> Nicola Robinson, GB   | 18:00 - 18:15 |
| WS17.06 | <b>Impact of elexacaftor/tezacaftor/ivacaftor on lung-recruited neutrophils in cystic fibrosis</b><br><i>Abstract Presenter:</i> Alexandre Cammarata-Mouchtouris, US   | 18:15 - 18:30 |

*Workshop*

17:00 - 18:30

R2

**WS18 - WS18: Alternative new therapeutic approaches**

*Chair:* Batsheva Kerem, IL

*Chair:* Margarida Amaral, PT

- |         |  |               |
|---------|--|---------------|
| WS18.01 | <b>Manufacturing and device development of SPL84-23-1, an inhaled antisense oligonucleotide, supporting first-in-human clinical study in cystic fibrosis patients carrying the 3849 mutation</b><br><i>Abstract Presenter:</i> Gili Hart, IL | 17:00 - 17:15 |
| WS18.02 | <b>A PI3Ky mimetic peptide triggers CFTR gating, bronchodilation and reduced inflammation in obstructive airway diseases</b><br><i>Abstract Presenter:</i> Alessandra Murabito, IT   | 17:15 - 17:30 |

WS18.03	<b>ETD001: a long-acting inhaled ENaC blocker is well tolerated in humans</b> <i>Abstract Presenter:</i> Paul Russell, GB	17:30 - 17:45
WS18.04	<b>Harnessing CRISPR-Cas9 technology to revert F508del-CFTR defect</b> <i>Abstract Presenter:</i> Anna Cereseto, IT	17:45 - 18:00
WS18.05	<b>Linking the compound database CandActCFTR and CFTR lifecycle map to predict possible active compound combinations</b> <i>Abstract Presenter:</i> Liza Vinhoven, DE	18:00 - 18:15
WS18.06	<b>Fully automated analysis of airway-artery dimensions on chest-computed tomography in preschool children with cystic fibrosis to evaluate the effect of inhaled hypertonic saline</b> <i>Abstract Presenter:</i> Yuxin Chen, NL	18:15 - 18:30

*Workshop*

17:00 - 18:30

R3

**WS19 - WS19: Monitoring lung function and structure - where are we?***Chair:* Alexander Horsley, GB*Chair:* Rikke Mulvad Sandvik, DK

WS19.01	<b>Prospective measurement of lung function in 0-4 year-old Danish children with cystic fibrosis</b> <i>Abstract Presenter:</i> Rikke Mulvad Sandvik, DK	17:00 - 17:15
WS19.02	<b>Impact of corrected multiple breath nitrogen washout (MBW) software on assessment of under/unventilated lung units (UVLU) with the MBWShX</b> <i>Abstract Presenter:</i> Christopher Short, GB	17:15 - 17:30
WS19.03	<b>Respiratory impedance analysis at 5Hz may reveal ventilation inhomogeneity in patients with cystic fibrosis</b> <i>Abstract Presenter:</i> Elpis Hatziagorou, GR	17:30 - 17:45
WS19.04	<b>Lung ultrasound in cystic fibrosis bronchiectasis</b> <i>Abstract Presenter:</i> Ioana Mihaela Ciuca, RO	17:45 - 18:00
WS19.05	<b>Arterialised partial pressure of oxygen: an alternative to FEV<sub>1</sub>% for tracking cystic fibrosis lung disease in childhood?</b> <i>Abstract Presenter:</i> René Gaupmann, AT	18:00 - 18:15
WS19.06	<b>Validation of airway-artery algorithm to detect and monitor airway disease on chest computed tomography in the ataluren cystic fibrosis cohort</b> <i>Abstract Presenter:</i> Qianting Lv, NL	18:15 - 18:30

*Workshop*

17:00 - 18:30

R4

**WS20 - WS20: Complex Psychosocial/Nursing case studies***Chair:* Nichola MacDuff, GB*Chair:* Urszula Borawska-Kowalczyk, PL

WS20.01	<b>Empowering self-management using intensive support in a</b>	17:00 - 17:15
---------	--	---------------

	<b>patient with challenging Cystic Fibrosis-Related Diabetes and renal failure</b>	
	<i>Abstract Presenter:</i> Joanna Snowball, GB	
WS20.02	<b>Input supporting a young person with increased cough suppression in the context of COVID-19</b>	17:15 - 17:30
	<i>Abstract Presenter:</i> Amy Shayle, GB	
WS20.03	<b>What to hope for when there is no hope</b>	17:30 - 17:45
	<i>Abstract Presenter:</i> Edwina Landau, IL	
WS20.04	<b>Enhancing self-compassion and limiting self-criticism in adults with cystic fibrosis decreases the likelihood of hospitalisation</b>	17:45 - 18:00
	<i>Abstract Presenter:</i> Michail Mantzios, GB	
WS20.05	<b>Cystic fibrosis, lockdown and CFTR modulators - a perfect storm</b>	18:00 - 18:15
	<i>Abstract Presenter:</i> Maggie Hufton, GB	
WS20.06	<b>Co-infection with <i>Nocardia farcinia</i> and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis</b>	18:15 - 18:30
	<i>Abstract Presenter:</i> James Chapman, GB	
<i>Workshop</i>		
17:00 - 18:30		R5
<b>WS21 - WS21: Potpourri of genetics and biomarkers</b>		
<i>Chair:</i> Francois Vermeulen, BE		
WS21.02	<b>Cystic fibrosis modifier genes and bacterial infections in Spanish patients</b>	17:15 - 17:30
	<i>Abstract Presenter:</i> Eva Granizo-Rodriguez, ES	
WS21.04	<b>Molecular characterisation of <i>CFTR</i> gene in the Argentinian population: impact of local variants in the sensitivity of genetic testing</b>	17:45 - 18:00
	<i>Abstract Presenter:</i> Carolina Crespo, AR	
WS21.05	<b>Prospective comparison of two sweat test methods</b>	18:00 - 18:15
	<i>Abstract Presenter:</i> Julie Carbonez, BE	
WS21.06	<b>Theß-adrenergic sweat secretion test using the AutoBuSTeD software is a novel, high-sensitive CFTR biomarker for patients with inconclusive CFTR genotype and sweat chloride concentration</b>	18:15 - 18:30
	<i>Abstract Presenter:</i> Sophia Pallenberg, DE	
<i>Workshop</i>		
17:00 - 18:30		R6
<b>WS22 - WS22: Late Breaking Science</b>		
<i>Chair:</i> Jane Davies, GB		
<i>Chair:</i> Kors Van der Ent, NL		
WS22.01	<b>ALPINE2: efficacy and safety of 14-day vs 28-day aztreonam for inhalation solution for <i>Pseudomonas aeruginosa</i> eradication in children and adolescents with cystic fibrosis</b>	17:00 - 17:18
	<i>Abstract Presenter:</i> Francis Gilchrist, GB	

---

WS22.02	<b>Colonization dynamics of <i>Pseudomonas aeruginosa</i> clinical isolates in a CF-derived airway model</b> <i>Abstract Presenter:</i> Filipa Simões, DK	17:18 - 17:36
WS22.03	<b>The effect of dual-CFTR modulators on airway bacteriology in Copenhagen CF patients</b> <i>Abstract Presenter:</i> Maria Pals Bendixen, DK	17:36 - 17:54
WS22.04	<b>Effect of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) on Annual Rate of Lung Function Decline in People with Cystic Fibrosis</b> <i>Abstract Presenter:</i> Tim Lee, GB	17:54 - 18:12
WS22.05	<b>Real-world safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis: interim results of a long-term registry-based study</b> <i>Abstract Presenter:</i> Julie K. Bower, US	18:12 - 18:30

**Saturday, 11. June 2022***Symposium*

09:00 - 10:30

R1

**S25 - Symposium 25 - What's new with fungi in cystic fibrosis****Objectives:****At the end of the session, the participant will be able to:**

- Synthesize knowledge on the mycobiome in people with cystic fibrosis
- Appraise the changing epidemiology in CF fungal disease induced by CFTR modulators
- Identify the characteristics of *Exophiala* infection and its treatment
- Formulate an opinion on combination of antifungal therapy
- Understand the relevance of fungal pathogens in people with CF.

*Chair:* Jean Philippe Bouchara, FR*Chair:* Miriam Moffatt, GB**The fungal airway microbiome in cystic fibrosis**

09:00 - 09:22

*Speaker:* Françoise Botterel, FR**What about CF Fungal Disease in the age of CFTR Modulators**

09:22 - 09:44

*Speaker:* Amelia Bercusson, GB***Exophiala* spp. in cystic fibrosis**

09:44 - 10:06

*Speaker:* Jean Philippe Bouchara, FR**Combination of antifungal therapy in cystic fibrosis**

10:06 - 10:30

*Speaker:* Carsten Schwarz, DE*Symposium*

09:00 - 10:30

R2

**S26 - Symposium 26 - Women's health****At the end of the session, the participant will be able to:**

- Identify the difference in outcomes according to gender in cystic fibrosis
- Discuss the current evidence regarding fertility and contraception advice for people with cystic fibrosis
- Apply best practice advice to the management of pregnancy in cystic fibrosis
- Appraise the current evidence regarding CFTR modulator use in pregnancy

*Chair:* Kris De Boeck, BE*Chair:* Peter Middleton, AU**The issue of the gender gap in CF care**

09:00 - 09:22

*Speaker:* Isabelle Fajac, FR**Fertility and contraception**

09:22 - 09:44

*Speaker:* Peter Middleton, AU**Management of pregnancy in cystic fibrosis**

09:44 - 10:06

*Speaker:* Michal Shteinberg, IL**CFTR modulator therapy and pregnancy - Knowns and unknowns**

10:06 - 10:30

*Speaker:* Jennifer Taylor-Cousar, US

## Symposium

09:00 - 10:30

R3

**S27 - Symposium 27 - Master Class in Clinical CF - Case Studies****At the end of the session, the participant will be able to:**

1. Describe best practice in challenging clinical cases
2. Discuss alternative approaches to management in challenging clinical cases
3. Evaluate different management strategies in the clinical care of people with cystic fibrosis
4. Synthesize the best management strategy for people with CF who have complex medical challenges

Chair: Peter Barry, GB

**Biofilm infection of a central venous port-catheter caused by *Mycobacterium avium* complex in an immunocompetent child with cystic fibrosis** 09:00 - 09:18

Speaker: Alexandra Kavvalou, DE

Discussant: Ian Balfour-Lynn, GB

**Don't fall asleep, this is the case you are weighting for!** 09:18 - 09:36

Speaker: Daniel Tewkesbury, GB

Discussant: Barry Plant, IE

**Intronic Variant Analysis; A Route to Diagnosis** 09:36 - 09:54

Speaker: Abbie Stephens, GB

Discussant: Silvia Gartner, ES

**Successful individualized dose reduction of elexacaftor/tezacaftor/ ivacaftor in cystic fibrosis patients in response to self-reported anxiety** 09:54 - 10:12

Speaker: Hisham Ibrahim, IE

Discussant: Lieven Dupont, BE

**Inflammation and leucocytoclastic vasculitis in a young cystic fibrosis patient: cause or consequence of severe lung disease?** 10:12 - 10:30

Speaker: Mariska Delausnay, BE

Discussant: Peter Barry, GB

## Symposium

09:00 - 10:30

R4

**S28 - Symposium 28 - Liver disease in cystic fibrosis**

Chair: Jaroslaw Walkowiak, PL

Chair: Carla Colombo, IT

**Pathogenesis and clinical manifestations of liver disease in paediatrics** 09:00 - 09:22

Speaker: Carla Colombo, IT

**Is liver disease in adulthood different?** 09:22 - 09:44

Speaker: Philippe Sogni, FR

**Radiological approaches to diagnose and monitor liver disease - dilemmas...** 09:44 - 10:06

Speaker: Dominique Debray, FR

**CFTR modulators: a promotor or a cure of CF liver disease?** 10:06 - 10:30

Speaker: Frank Bodewes, NL

## Symposium

09:00 - 10:30

R5

**S29 - Symposium 29 - Epidemiology of screening and CF genotype****At the end of the session, the participant will be able to:**

- Discuss differences in newborn screening practices across Europe.
- Summarise global patterns in CFTR mutations.
- Describe the role of different CFTR mutations, including rare mutations, on CF diagnosis and disease progression
- Recognise the role of registries in assessing effectiveness on CFTR modulators, including by genotype.

Chair: Andreas Jung, CH

Chair: Kevin Southern, GB

**Improving the quality and performance of newborn screening for CF across Europe**

09:00 - 09:22

Speaker: Jürg Barben, CH

**Impact of nonsense mutations on the evolution of lung disease**

09:22 - 09:44

Speaker: Isabelle Sermet-Gaudelus, FR

**Worldwide analysis of CFTR mutations and application to screening**

09:44 - 10:06

Speaker: Milan Jr Macek, CZ

**The role of CF Registry in assessing effectiveness of targeted (CFTR modulator) therapy, and impacts by CF genotype**

10:06 - 10:28

Speaker: Elizabeth Cromwell, US

## Symposium

09:00 - 10:30

R6

**S30 - Symposium 30 - Targets for CFTR bypass therapy****At the end of the session, the participant will be able to:**

- Evaluate whether alternative pathways for transmembrane anion transport can be targeted to rehydrate CF airway epithelia
- Summarise progress towards developing small molecule ENaC inhibitors to prevent dehydration of airway epithelia in CF
- Analyse the potential of targeting ATP12A to restore host defence mechanisms to CF airway epithelia

Chair: David Sheppard, GB

Chair: Marcel Bijvelds, NL

**Modulation of TMEM16A to substitute for CFTR dysfunction in CF epithelia**

09:00 - 09:22

Speaker: Raimund Dutzler, CH

**SLC26A9 and SLC6A14 as gene modifiers of disease severity and drug response in cystic fibrosis**

09:22 - 09:44

Speaker: Harriet Corvol, FR

**Innovative ENaC inhibitors to suppress dehydration of CF epithelia**

09:44 - 10:06

Speaker: Henry Danahay, GB

**ATP12A as a therapeutic target in CF lung disease**

10:06 - 10:30

Speaker: Gilles Crambert, FR



*Closing Plenary*

11:00 - 12:30

R1

**Closing Plenary***Chair:* Harm Tiddens, NL*Chair:* Isabelle Fajac, FR**ECFS standards for the provision of CFTR modulators**

11:00 - 11:30

*Speaker:* Kevin Southern, GB**Cystic fibrosis research and treatment, what is next?**

11:30 - 12:00

*Speaker:* Jeffrey Beekman, NL**ECFS President Address**

12:00 - 12:30

*Speaker:* Isabelle Fajac, FR*Closing Ceremony*

12:30 - 13:00

R1

**Closing Ceremony**